Steroid synthesis Thyroid synthesis Thyroid Function tests P th calcium metabolism Ca and phhos Insulin stru also receptor Glucagon Somatostatin Glut transporters Role of c peptide Lab diag of dm Oral glucose Hba1 c Glucagon receptors Metabolism of insulin, glucagon all metabolism Somatostatin metabolism explain me biochemstry of this topic like i dont know anything each and every topic explain me clearly

Reading File
general-purpose

You are a medical biochemistry expert. Search the medical textbook library database and retrieve detailed content on these topics: 1. Steroid hormone synthesis (cholesterol to steroid hormones, steroidogenesis pathway) 2. Thyroid hormone synthesis (iodine trapping, organification, coupling, T3/T4 formation) 3. Thyroid function tests (TSH, T3, T4, free T4, TRH stimulation, interpretation) Use query_library_db with FTS searches like: - SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 40) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH 'steroid synthesis cholesterol' ORDER BY rank LIMIT 5 - Similarly for 'thyroid hormone synthesis iodination' - Similarly for 'thyroid function tests TSH T3 T4' - Similarly for 'steroidogenesis pathway cortisol aldosterone' Then read the actual file blocks using read_file with the paths and line numbers returned. Read at least 100-150 lines per block for each topic. Return a DETAILED summary of everything you find for each of the 3 topics - mechanisms, pathways, enzymes, clinical significance. Include exact biochemical steps.

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Here is your complete, beginner-to-expert guide on all the topics you asked about. Read it top to bottom - it builds progressively.

🧬 COMPLETE BIOCHEMISTRY GUIDE: Hormones, Metabolism & Diabetes

Based on Guyton & Hall, Harper's Biochemistry, Ganong's Physiology, Basic Medical Biochemistry 6e, Tietz Laboratory Medicine, and other authoritative textbooks.

PART 1: STEROID HORMONE SYNTHESIS

What is a steroid hormone? Start from scratch.

Think of steroid hormones as chemical messengers made from cholesterol - the same fat-like molecule that forms your cell membranes. Every single steroid hormone in your body - cortisol, aldosterone, testosterone, estrogen, progesterone - is built from cholesterol. This is important: steroid hormones are lipid-soluble, so they can cross cell membranes directly and act inside the cell (unlike protein hormones that knock on the door from outside).

Where are they made?

Gland/OrganHormones Produced
Adrenal Cortex (outer layer)Cortisol, Aldosterone, DHEA
Testes (Leydig cells)Testosterone
Ovaries (granulosa cells)Estrogen, Progesterone
PlacentaProgesterone, Estriol

The Big Picture Pathway

CHOLESTEROL (C27)
      ↓  [RATE-LIMITING STEP: StAR protein moves cholesterol into mitochondria]
      ↓  [Enzyme: CYP11A1 = P450scc, in inner mitochondrial membrane]
PREGNENOLONE  ← This is the "mother of all steroids"
      ↓  [3Ξ²-HSD enzyme, in smooth ER]
PROGESTERONE
      ↓ splits into 3 pathways based on which zone of adrenal gland
  β”Œβ”€β”€β”€β”΄β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
  ↓                                ↓                  ↓
GLUCOCORTICOIDS            MINERALOCORTICOIDS      ANDROGENS/ESTROGENS
(Zona Fasciculata)          (Zona Glomerulosa)      (Zona Reticularis)
CORTISOL                    ALDOSTERONE             DHEA β†’ Testosterone β†’ Estradiol

Step-by-Step: Cholesterol to Each Hormone

Step 1 - The Rate-Limiting Step

  • StAR protein (Steroidogenic Acute Regulatory protein) physically shuttles cholesterol from the outer to the inner mitochondrial membrane
  • This is the first thing ACTH triggers - no StAR activity = no steroid synthesis
  • Think of StAR as the "gate opener" - without it, the raw material (cholesterol) can't enter the factory (mitochondria)

Step 2 - Cholesterol β†’ Pregnenolone

  • Enzyme: P450scc (CYP11A1) - "scc" = side chain cleavage
  • It snips off a 6-carbon piece from cholesterol (C27) to make pregnenolone (C21)
  • Needs: NADPH + Oxygen
  • Location: Inner mitochondrial membrane

Step 3 - Pregnenolone β†’ Progesterone

  • Enzyme: 3Ξ²-HSD (3-beta hydroxysteroid dehydrogenase) + isomerase
  • Converts the Ξ”5 compound (pregnenolone) into a Ξ”4 compound (progesterone)
  • Location: Smooth endoplasmic reticulum

Now the 3 Pathways Diverge:

Pathway A - CORTISOL (Zona Fasciculata - stress hormone)

Progesterone
  ↓ CYP17A1 (17Ξ±-hydroxylase) - adds OH at C17
17Ξ±-Hydroxyprogesterone (17-OHP)
  ↓ CYP21A2 (21-hydroxylase) - adds OH at C21
11-Deoxycortisol
  ↓ CYP11B1 (11Ξ²-hydroxylase) - adds OH at C11, in mitochondria
CORTISOL βœ“
  • Important exam fact: CYP21A2 deficiency = most common CAH (Congenital Adrenal Hyperplasia). If you can't make cortisol/aldosterone, all precursors flood into the androgen pathway β†’ virilization + salt-wasting crisis.

Pathway B - ALDOSTERONE (Zona Glomerulosa - salt hormone)

Progesterone
  ↓ CYP21A2 (21-hydroxylase)
11-Deoxycorticosterone (DOC)
  ↓ CYP11B1 (11Ξ²-hydroxylase)
Corticosterone
  ↓ CYP11B2 (Aldosterone synthase) ← ONLY exists in zona glomerulosa!
ALDOSTERONE βœ“
  • Key: Zona glomerulosa lacks CYP17A1 (17Ξ±-hydroxylase) so it can't make cortisol or androgens - it's wired only for aldosterone.

Pathway C - ANDROGENS/ESTROGENS (Zona Reticularis + Gonads)

17-Hydroxypregnenolone
  ↓ CYP17A1 (now acting as 17,20-lyase - second function)
DHEA (C19 - weak androgen)
  ↓ 3Ξ²-HSD
Androstenedione
  ↓ 17Ξ²-HSD (in gonads)
TESTOSTERONE
  ↓ CYP19A1 (Aromatase) in ovarian granulosa cells
ESTRADIOL (C18 - most potent estrogen)
  
OR
  ↓ 5Ξ±-Reductase in prostate/skin
DHT (Dihydrotestosterone - most potent androgen)

Carbon Number Rule (Easy Memory)

  • C21 = Glucocorticoids (cortisol) + Mineralocorticoids (aldosterone) + Progestogens
  • C19 = Androgens (testosterone, DHEA)
  • C18 = Estrogens (estradiol) - have aromatic ring A

Regulation - Who Controls All This?

HPA Axis (Glucocorticoids): Stress β†’ Hypothalamus releases CRH β†’ Pituitary releases ACTH β†’ Adrenal makes cortisol β†’ Cortisol feeds back to inhibit both CRH and ACTH (negative feedback loop)
RAAS (Aldosterone): Low blood volume β†’ Kidney releases Renin β†’ Renin cleaves Angiotensinogen β†’ Angiotensin I β†’ ACE (lung) β†’ Angiotensin II β†’ Stimulates CYP11B2 β†’ Aldosterone production

PART 2: THYROID HORMONE SYNTHESIS

What are thyroid hormones?

Unlike steroids (made from cholesterol), thyroid hormones are made from tyrosine (an amino acid) + iodine. They regulate your basal metabolic rate - essentially the speed at which every cell in your body runs.
  • T4 (Thyroxine) = 4 iodine atoms, made exclusively in thyroid, is a prohormone (not very active)
  • T3 (Triiodothyronine) = 3 iodine atoms, the active hormone, 80% comes from peripheral conversion of T4
Think of T4 as a "sleeping" version of the hormone that gets "activated" in tissues by removing one iodine atom.

The 6 Steps of Thyroid Hormone Synthesis

Where it happens

The thyroid gland is made up of spherical follicles. Each follicle is a balloon of cells (thyrocytes) surrounding a jelly-like substance called colloid - which contains thyroglobulin (Tg), a large protein that acts as the scaffold for making T3/T4.
BLOOD (Iodide I⁻) β†’ [STEP 1: TRAPPING] β†’ Inside thyrocyte β†’ [STEP 3: ORGANIFICATION]
β†’ COLLOID (Thyroglobulin + Iodine) β†’ [STEP 4: COUPLING] β†’ T4/T3 stored on Tg
β†’ [STEP 5: SECRETION] β†’ Free T4/T3 released into blood
β†’ [STEP 6: PERIPHERAL CONVERSION] β†’ T4 β†’ T3 in liver/kidney

Step 1 - Iodide Trapping (Active Transport)

  • Transporter: NIS (Sodium-Iodide Symporter) on the basolateral membrane (blood side)
  • Brings 2 Na⁺ + 1 I⁻ into the cell together (symport)
  • Concentrates iodide 20-40 times higher inside the cell than in blood
  • Driven by the Na⁺ gradient (created by Na/K-ATPase)
  • Pendrin transports I⁻ from cell into the colloid (apical membrane)
  • Regulated by: TSH increases NIS activity; excess iodine inhibits it (Wolff-Chaikoff effect)

Step 2 - Thyroglobulin Synthesis

  • Thyroglobulin (660 kDa glycoprotein) made in rough ER of thyrocyte
  • Processed in Golgi, then secreted by exocytosis into the colloid
  • Contains 123 tyrosine residues, but only 4-8 will actually become thyroid hormones
  • Think of Tg as a "tyrosine delivery board" waiting to be iodinated

Step 3 - Organification of Iodide

  • Enzyme: TPO (Thyroid Peroxidase) at the apical membrane (colloid side)
  • TPO uses Hβ‚‚Oβ‚‚ (made by DUOX2 enzyme) to oxidize I⁻ β†’ reactive iodine (I⁰)
  • Reactive iodine attaches to tyrosine residues on Tg:
    • One iodine added β†’ MIT (Monoiodotyrosine)
    • Two iodines added β†’ DIT (Diiodotyrosine)
  • Blocked by: Propylthiouracil (PTU), Methimazole (anti-thyroid drugs)

Step 4 - Coupling (Making T3 and T4)

  • Same enzyme: TPO catalyzes coupling
  • Two iodinated tyrosines join together on the Tg scaffold:
    • DIT + DIT β†’ T4 (thyroxine, 4 iodines) - most abundant
    • MIT + DIT β†’ T3 (3,5,3β€²-triiodothyronine, 3 iodines) - active form
    • DIT + MIT β†’ rT3 (reverse T3, biologically inactive)
  • This all happens while tyrosines are still attached to thyroglobulin

Step 5 - Secretion

  1. TSH stimulates thyrocytes to endocytose (eat) the colloid
  2. Colloid vesicles fuse with lysosomes β†’ proteases digest thyroglobulin
  3. Free T4 and T3 are released and diffuse into the bloodstream
  4. MIT and DIT are NOT secreted - iodotyrosine deiodinase strips their iodine off and recycles it back into new hormone synthesis

Step 6 - Peripheral Conversion (T4 β†’ T3)

  • T4 is a prohormone; it must be converted to T3 to be active
  • 80% of circulating T3 comes from this conversion in liver, kidney, muscle
  • Deiodinases contain selenocysteine (selenium):
EnzymeLocationMakes
D1Liver, kidney, thyroidT3 (main circulating T3 source)
D2Brain, pituitary, brown fatLocal T3 (especially in brain)
D3Brain, placentaInactive rT3 (inactivates T4)

How Thyroid Hormones Work (Receptor Mechanism)

  • T3 enters the cell β†’ binds nuclear thyroid hormone receptor (TR)
  • TR-T3 complex binds to Thyroid Hormone Response Elements (TREs) in DNA
  • Results: Upregulates genes for metabolic enzymes, Na/K-ATPase, cardiac proteins, growth hormones

Transport in Blood

Thyroid hormones are hydrophobic - they need carrier proteins:
  • TBG (Thyroxine-binding globulin) - binds 67% of T4, 46% of T3
  • Transthyretin - binds 20% of T4
  • Albumin - binds 13% of T4, 53% of T3
  • Only the free fraction (0.02% of T4, 0.2% of T3) is biologically active

HPT Axis (Regulation)

Hypothalamus: TRH (tripeptide)
      ↓
Anterior Pituitary (thyrotrophs): TSH (glycoprotein, Ξ±+Ξ² subunits)
      ↓
Thyroid Gland: T4 (mainly) + small T3
      ↑ Negative feedback (free T3/T4 suppress both TRH and TSH)

PART 3: THYROID FUNCTION TESTS

Why do we test thyroid function?

Because thyroid disorders are extremely common. The key insight is that TSH and free T4 have an inverse logarithmic relationship - a tiny drop in free T4 causes a huge surge in TSH. This makes TSH extremely sensitive.

The Tests - One by One

1. TSH (Thyroid-Stimulating Hormone)

  • Normal range: 0.35-5.0 mIU/L
  • The most sensitive test for thyroid dysfunction
  • HIGH TSH = thyroid is failing = the pituitary is screaming louder = Primary Hypothyroidism
  • LOW TSH = thyroid is overactive = the pituitary is quiet = Primary Hyperthyroidism
  • Exception: If the pituitary itself is diseased (central hypothyroidism), TSH may be low despite low T4 - always check TSH + FT4 together if you suspect pituitary disease

2. Free T4 (FT4)

  • Normal range: 12-28 pmol/L (0.8-2.4 ng/dL)
  • Measures only the unbound, biologically active T4
  • More reliable than Total T4 because it's not affected by binding protein changes (e.g., pregnancy raises TBG β†’ raises Total T4 but Free T4 stays normal)

3. Free T3 (FT3)

  • Normal range: 3-9 pmol/L
  • Used when: T3 toxicosis suspected (patient is hyperthyroid with normal FT4 but elevated FT3)

4. Total T4 and Total T3

  • Measures bound + free hormone
  • Less useful because binding protein changes confuse the results
  • Estrogen (pregnancy, OCP) β†’ ↑ TBG β†’ ↑ Total T4/T3 (but patient is euthyroid, FT4 normal!)
  • Androgens, glucocorticoids β†’ ↓ TBG β†’ ↓ Total T4/T3 (but patient is still euthyroid)

5. Reverse T3 (rT3)

  • Elevated rT3 + Low T3 + Normal T4 = Euthyroid Sick Syndrome (nonthyroidal illness)
  • In critical illness, starvation, major surgery: the body shunts T4 away from T3 (active) toward rT3 (inactive) to conserve energy

6. TRH Stimulation Test

  • Inject 500 ΞΌg TRH IV β†’ measure TSH at 0, 30, 60 min
  • Normal: TSH rises by β‰₯6 mIU/L at 30 min
  • Blunted response: primary hyperthyroidism OR pituitary disease
  • Exaggerated response: primary hypothyroidism
  • Largely replaced by modern sensitive TSH assays

7. Thyroid Antibodies

  • Anti-TPO (aTPO): Positive in Hashimoto's (>80%) and Graves' disease
  • TSI (Thyroid-Stimulating Immunoglobulin): Diagnostic for Graves' disease - these antibodies mimic TSH and stimulate the gland continuously
  • Anti-thyroglobulin (ATG): Hashimoto's; also interferes with Tg measurements used in thyroid cancer monitoring

Interpretation Table (Memorize This)

ConditionTSHFT4FT3
Primary Hyperthyroidism↓↓↑↑
T3 Toxicosis↓Normal↑↑
Subclinical Hyperthyroidism↓NormalNormal
Primary Hypothyroidism↑↑↓↓
Subclinical Hypothyroidism↑NormalNormal
Central (Pituitary) Hypothyroidism↓ or Normal↓↓
Graves' disease↓↑↑
Euthyroid Sick SyndromeVariable ↓↓↓↓
Pregnancy (↑TBG)NormalNormal FT4Total T4 ↑↑

PART 4: PTH AND CALCIUM METABOLISM

Why is calcium so important?

Calcium is not just for bones. It is required for:
  • Muscle contraction (including heart muscle)
  • Nerve impulse transmission
  • Blood clotting (coagulation cascade)
  • Cell signaling (second messenger)
  • Enzyme activation
Your body maintains blood calcium in a very tight range: 8.5-10.5 mg/dL (2.1-2.6 mmol/L).

Three Organs Control Calcium: Bone, Kidney, Intestine

Three hormones orchestrate this:
  1. PTH (Parathyroid Hormone) - raises calcium
  2. Calcitriol (1,25-(OH)β‚‚-Vitamin D) - raises calcium
  3. Calcitonin - lowers calcium (minor role in adults)

PTH: The Emergency Calcium Raiser

Structure

  • PTH is an 84 amino acid polypeptide made by chief cells of the 4 parathyroid glands (tiny glands behind the thyroid)
  • The biologically active portion is the first 34 amino acids (N-terminal)

What triggers PTH release?

  • Low blood Ca²⁺ β†’ chief cells detect this via CaSR (Calcium-Sensing Receptor) on their surface
  • Low Ca²⁺ β†’ CaSR inactive β†’ PTH released
  • High Ca²⁺ β†’ CaSR activated β†’ PTH suppressed

PTH's 3 Target Actions

TargetActionEffect
BoneActivates osteoclasts (bone breakers)Releases Ca²⁺ AND PO₄³⁻ from bone
Kidney (DCT)Increases Ca²⁺ reabsorption; DECREASES PO₄³⁻ reabsorption (phosphaturic effect)Saves Ca²⁺, loses PO₄³⁻
Kidney (PCT)Activates 1Ξ±-hydroxylase β†’ converts 25-OH-Vitamin D to 1,25-(OH)β‚‚-Vitamin D (Calcitriol)Indirectly increases intestinal Ca²⁺ absorption
Key point: PTH raises calcium but LOWERS phosphate (because kidney dumps phosphate). So in hyperparathyroidism: Ca²⁺ ↑, POβ‚„ ↓.

PTH Mechanism of Action

  • PTH receptor (PTH1R) is a GPCR (G-protein coupled receptor)
  • Binds PTH β†’ activates Gs β†’ cAMP ↑ β†’ PKA activation
  • Also activates Gq β†’ PLC β†’ IP₃ β†’ Ca²⁺ release + PKC activation

Vitamin D - The Intestinal Calcium Hero

Activation Pathway

Skin: UV light + 7-dehydrocholesterol β†’ Cholecalciferol (Vitamin D3)
  ↓ Liver: 25-hydroxylase
25-hydroxyvitamin D (Calcidiol) ← this is what you measure in blood tests!
  ↓ Kidney: 1Ξ±-hydroxylase (activated by PTH, low POβ‚„, low Ca)
1,25-dihydroxyvitamin D (Calcitriol) ← the ACTIVE form

Actions of Calcitriol

  • Intestine: Increases synthesis of calbindin-D (calcium transport protein) and TRPV6 channels β†’ increases Ca²⁺ absorption (up to 80% of dietary calcium!)
  • Bone: At normal levels, promotes bone mineralization; at high levels, works with PTH to release Ca from bone
  • Kidney: Mild increase in Ca²⁺ reabsorption
  • Parathyroid gland: Suppresses PTH synthesis (negative feedback)

Calcitonin - The Bone Protector

  • Made by C-cells (parafollicular cells) of the thyroid gland
  • Released when Ca²⁺ is HIGH
  • Actions: Inhibits osteoclasts β†’ reduces bone resorption; increases renal Ca excretion
  • Clinical note: Calcitonin's role in adult humans is minor; it's more important in growing children and pregnant/lactating women. Used therapeutically in Paget's disease and hypercalcemia.

Calcium and Phosphate - The Inverse Relationship

Ca Γ— Phosphate product (ion product) = approximately 30-40 in normal plasma
When you raise one, the other tends to fall (because of PTH). This is why:
  • In hyperparathyroidism: Ca ↑, POβ‚„ ↓
  • In hypoparathyroidism: Ca ↓, POβ‚„ ↑
  • In Vitamin D toxicity: Both Ca AND POβ‚„ rise (because Vit D raises both)
  • In Chronic Kidney Disease: Kidneys can't make calcitriol + can't excrete POβ‚„ β†’ POβ‚„ ↑, Ca ↓ β†’ Secondary hyperparathyroidism

Phosphate Regulation Summary

HormoneEffect on Blood PhosphateMechanism
PTH↓ (phosphaturia)Inhibits NaPi cotransporter in kidney PCT
Calcitriol↑Increases intestinal POβ‚„ absorption
FGF-23 (from bone)↓↓Major phosphaturic hormone; also inhibits 1Ξ±-hydroxylase

PART 5: INSULIN - STRUCTURE AND RECEPTOR

What is insulin? The basics.

Insulin is a polypeptide hormone made by beta (Ξ²) cells in the islets of Langerhans of the pancreas. It is the key that "unlocks" cells to let glucose in. Without insulin, glucose can't enter most cells - it stays in the blood, causing diabetes mellitus.
The pancreatic islets contain:
  • Ξ± cells (25%) - make Glucagon
  • Ξ² cells (60%) - make Insulin
  • Ξ΄ cells (10%) - make Somatostatin
  • PP cells (5%) - make Pancreatic polypeptide

Insulin Structure - Built Like a Two-Strand Rope

Human insulin:
  • Molecular weight: 5,808 Da
  • Two chains: A chain (21 amino acids) + B chain (30 amino acids)
  • Connected by: 2 disulfide bonds (between chains) + 1 within the A chain
  • If you split the two chains apart, insulin completely loses its activity
Proinsulin structure showing A chain, B chain, and C peptide

How Insulin is Made - The Biosynthesis Pathway

Gene on chromosome 11
      ↓ Transcription + Translation on ribosomes (RER)
PREPROINSULIN (110 amino acids, MW ~11,500)
      ↓ Signal peptide cleaved in ER lumen
PROINSULIN (86 amino acids, MW ~9,000) = A chain + B chain + C peptide
      ↓ Packaged in Golgi vesicles
      ↓ Cleavage by prohormone convertases (PC1 and PC2) + CPE
INSULIN (A+B chains, MW 5,808) + C PEPTIDE (31 amino acids)
      ↓ Both secreted together in equimolar amounts from secretory granules
Key point: Insulin and C-peptide are released in equimolar amounts (1:1 ratio). This is important for diagnosis!

What is C-Peptide? (Role of C-Peptide)

C-peptide = "Connecting peptide" - the middle chunk of proinsulin that gets cut out.
Why does it matter?
  1. Diagnostic use: Injected insulin has no C-peptide. So if a diabetic patient has high insulin but low C-peptide, they're injecting insulin (factitious hypoglycemia or insulin misuse). If insulin AND C-peptide are both high, the body is making too much insulin (insulinoma).
  2. Beta cell function marker: C-peptide measurement tells you how much insulin the pancreas is making. Because C-peptide has a longer half-life (~35 min vs. ~5 min for insulin), it's easier to measure.
  3. Biological activity: C-peptide binds a G-protein-coupled receptor and activates Na/K-ATPase and endothelial nitric oxide synthase (eNOS) β†’ may protect against diabetic nephropathy and neuropathy. This biological role is still being studied.

Insulin Secretion - How Does Glucose Trigger It?

Glucose enters Ξ²-cell via GLUT2 (passive)
      ↓
Glucokinase (Hexokinase IV) phosphorylates glucose β†’ Glucose-6-phosphate
      ↓
Glycolysis + TCA cycle β†’ ATP production
      ↓
↑ ATP/ADP ratio
      ↓
ATP-sensitive K⁺ channel (KATP channel) CLOSES
      ↓
β-cell membrane DEPOLARIZES (K⁺ can't leave)
      ↓
Voltage-gated Ca²⁺ channels OPEN
      ↓
Ca²⁺ floods into β-cell
      ↓
Insulin granules FUSE with membrane β†’ EXOCYTOSIS of insulin + C-peptide
Two phases of insulin secretion:
  • Phase 1 (First phase, 3-5 min): Rapid dump of pre-stored insulin granules (immediate response to glucose rise)
  • Phase 2 (15 min to 2 hrs): Slower, sustained secretion from newly synthesized + stored insulin

The Insulin Receptor - How Insulin Acts

The insulin receptor is a receptor tyrosine kinase (RTK) - one of the most important signaling systems in the body.

Structure

  • Heterotetramer: 2Ξ± subunits (extracellular, bind insulin) + 2Ξ² subunits (transmembrane + intracellular kinase domain)
  • Connected by disulfide bonds

Signal Transduction Cascade

Insulin binds to Ξ± subunit
      ↓
Conformational change activates Ξ² subunit tyrosine kinase
      ↓
Ξ² subunit AUTOPHOSPHORYLATES (phosphorylates itself on tyrosine residues)
      ↓
Phosphorylates IRS-1/IRS-2 (Insulin Receptor Substrate proteins)
      ↓
       β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
       ↓                             ↓
PI3K β†’ PIP3 β†’ PDK1 β†’ Akt          Grb2/SOS β†’ Ras β†’ Raf β†’ MEK β†’ ERK
(Metabolic effects:                 (Mitogenic effects:
 GLUT4 translocation,                cell growth,
 glycogen synthesis,                 gene expression,
 lipogenesis,                        differentiation)
 protein synthesis)
The most important metabolic effect: Akt phosphorylates AS160 β†’ releases GLUT4 vesicles from intracellular stores β†’ GLUT4 moves to the cell surface β†’ glucose enters the cell.

PART 6: GLUCAGON

What is glucagon? The opposite of insulin.

Glucagon is made by alpha (Ξ±) cells of the pancreatic islets. While insulin stores energy (anabolic), glucagon releases stored energy (catabolic) during fasting, exercise, and hypoglycemia.
Think of it this way:
  • Insulin = fed state hormone (glucose ↑ β†’ insulin ↑ β†’ store energy)
  • Glucagon = fasting state hormone (glucose ↓ β†’ glucagon ↑ β†’ release energy)

Glucagon Structure

  • 29 amino acid polypeptide
  • Made from proglucagon (158 amino acids) gene
  • Same proglucagon gene, but processed differently in intestinal L-cells β†’ makes GLP-1 (glucagon-like peptide 1) instead

What Stimulates Glucagon?

Stimulates GlucagonInhibits Glucagon
Low blood glucose (hypoglycemia)High blood glucose
Amino acids (especially alanine, arginine)Insulin
Fasting, exercise, stressSomatostatin
Epinephrine (Ξ±2-adrenergic)Free fatty acids
CortisolGLP-1

Glucagon Receptor and Mechanism

The glucagon receptor is a Class B GPCR (G-protein coupled receptor).
Glucagon binds glucagon receptor on hepatocyte
      ↓
GΞ±s protein activates Adenylyl Cyclase
      ↓
ATP β†’ cAMP ↑↑
      ↓
Protein Kinase A (PKA) activated
      ↓ (phosphorylates multiple enzymes simultaneously)
     β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
     ↓                                            ↓
GLYCOGENOLYSIS                             GLUCONEOGENESIS
(glycogen phosphorylase activated;         (PEP carboxykinase,
 phosphofructokinase-2 inhibited)          fructose-1,6-bisphosphatase activated)
     ↓                                            ↓
Glucose released from glycogen          New glucose made from
into blood                              amino acids, lactate, glycerol
Additional glucagon effects:
  • Lipolysis: Activates hormone-sensitive lipase β†’ releases fatty acids from adipose
  • Ketogenesis: Promotes fatty acid oxidation β†’ acetyl-CoA β†’ ketone bodies in liver
  • Protein catabolism: Promotes amino acid release from muscle for gluconeogenesis

Glucagon Metabolism (How is it broken down?)

  • Half-life: 3-6 minutes
  • Degraded primarily by: liver (first pass, ~60% removed) and kidneys
  • Mechanism: Proteolytic degradation by liver proteases and renal clearance
  • The short half-life means glucagon levels change very quickly in response to blood glucose

PART 7: SOMATOSTATIN

What is somatostatin? The "off switch."

Somatostatin is a universal inhibitory hormone - it shuts down multiple secretory processes simultaneously. It is made by:
  • Ξ΄ (delta) cells of the pancreatic islets
  • D cells of the stomach and intestine
  • Hypothalamus (inhibits growth hormone from pituitary)

Structure

  • Two forms: SS-14 (14 amino acids) and SS-28 (28 amino acids)
  • Both are cyclic peptides (amino and carboxy termini linked by a disulfide bridge)
  • SS-14 predominates in pancreas; SS-28 predominates in intestine

What Triggers Somatostatin Release?

  • High glucose, amino acids, fatty acids after a meal
  • Other GI hormones (CCK, secretin)
  • High glucagon or insulin (local paracrine effect)

Somatostatin's Effects - "SOMATOSTATIN Stops Everything"

TargetEffect
Pancreatic Ξ² cellsInhibits insulin secretion
Pancreatic Ξ± cellsInhibits glucagon secretion
PituitaryInhibits GH (growth hormone) and TSH release
StomachInhibits gastrin, HCl, pepsin secretion
IntestineInhibits secretin, CCK, VIP, motilin
LiverInhibits bile flow
GI motilitySlows gastric emptying, reduces splanchnic blood flow
Memory trick: Somatostatin is the "bucket of cold water" thrown on every secretory process after a meal.

Mechanism of Action

  • Somatostatin receptors (SSTR1-5) are GPCRs coupled to Gi (inhibitory G-protein)
  • Gi β†’ inhibits adenylyl cyclase β†’ cAMP ↓ β†’ PKA activity ↓
  • Also: Opens K⁺ channels β†’ hyperpolarization β†’ inhibits Ca²⁺ entry β†’ inhibits exocytosis
  • In Ξ± and Ξ² cells: the reduced cAMP + hyperpolarization directly suppresses hormone granule release

Somatostatin Metabolism

  • Half-life: extremely short, ~1-3 minutes in circulation
  • Degraded by peptidases in the blood and tissues
  • This is why octreotide (a synthetic analog with half-life 1.5 hours) and lanreotide (long-acting, monthly injection) were developed for clinical use
  • Clinical uses: acromegaly (excess GH), carcinoid tumors, VIPomas, glucagonomas, bleeding esophageal varices

PART 8: GLUT TRANSPORTERS

What are GLUT transporters?

Glucose is a large, polar molecule - it cannot freely cross the lipid bilayer of cell membranes. It needs special protein channels called GLUT transporters (Glucose Transporter proteins). These are facilitative transporters - they move glucose DOWN its concentration gradient (no energy needed).

The Key GLUT Transporters - A Complete Table

GLUTLocationKm for GlucoseCharacteristicsRegulation
GLUT1RBCs, brain (blood-brain barrier), placenta, all fetal tissues1 mM (low Km = high affinity)Constitutive (always on surface); baseline glucose transport; not regulated by insulinConstitutive
GLUT2Liver, pancreatic Ξ²-cells, kidney, small intestine15-20 mM (high Km = low affinity)"Glucose sensor" - only transports glucose when it's abundant; allows liver to buffer post-meal glucose; essential for insulin secretion triggerNot regulated by insulin
GLUT3Neurons (brain)1 mM (high affinity)Ensures neurons ALWAYS get glucose even when levels fallConstitutive
GLUT4Skeletal muscle, cardiac muscle, adipose tissue5 mMThe insulin-regulated transporter - stored in intracellular vesicles; moves to surface when insulin signalsInsulin-dependent!
GLUT5Small intestine (enterocytes), spermHigh KmFructose transporter (not glucose)Constitutive

The Magic of GLUT4 - Why Insulin Matters

At rest (no insulin):
  • GLUT4 vesicles sit in the cytoplasm, docked to intracellular membranes
  • Very few GLUT4 molecules on the cell surface
  • Little glucose enters muscle/fat cells
After a meal (insulin released):
Insulin β†’ IR β†’ IRS-1 β†’ PI3K β†’ PIP3 β†’ Akt β†’ phosphorylates AS160
      ↓
TBC1D4 (AS160) is inactivated
      ↓
Rab-GTPase proteins activated
      ↓
GLUT4 vesicles traffic to plasma membrane
      ↓
GLUT4 fuses with membrane (exocytosis)
      ↓
GLUT4 on surface increases 10-20 fold
      ↓
Glucose floods into muscle/fat cell
When insulin is removed β†’ GLUT4 is endocytosed back into the cell (recycled).
Clinical relevance: In Type 2 Diabetes, the Akt/AS160 signaling is impaired (insulin resistance) β†’ GLUT4 doesn't move to the surface β†’ cells starve despite normal/high insulin β†’ hyperglycemia.
Exercise effect: Exercise ALSO moves GLUT4 to the surface independently of insulin (via AMPK pathway). This is why exercise lowers blood glucose even without insulin.

PART 9: LABORATORY DIAGNOSIS OF DIABETES MELLITUS

ADA Diagnostic Criteria (any ONE of these criteria on TWO separate days):

TestDiabetesPrediabetesNormal
Fasting Plasma Glucose (FPG)β‰₯ 126 mg/dL (7.0 mmol/L)100-125 mg/dL (IFG)< 100 mg/dL
2-hr Plasma Glucose (OGTT)β‰₯ 200 mg/dL (11.1 mmol/L)140-199 mg/dL (IGT)< 140 mg/dL
HbA1cβ‰₯ 6.5% (48 mmol/mol)5.7-6.4%< 5.7%
Random Plasma Glucoseβ‰₯ 200 mg/dL WITH symptoms (polyuria, polydipsia, weight loss)--
Exception: For the random glucose β‰₯200 mg/dL WITH symptoms rule, only ONE measurement is needed (no need for confirmation on a second day).

Oral Glucose Tolerance Test (OGTT) - In Detail

Procedure

  1. Preparation: Patient fasts for 8-14 hours overnight; no heavy exercise 3 days prior; normal carbohydrate diet (β‰₯150g/day) for 3 days prior
  2. Fasting blood sample taken
  3. Patient drinks 75g anhydrous glucose dissolved in 250-300 mL water (within 5 minutes)
  4. Blood samples taken at 1 hour and 2 hours
  5. Patient sits quietly, no smoking during test

Interpretation

2-hour valueInterpretation
< 140 mg/dLNormal glucose tolerance
140-199 mg/dLIGT (Impaired Glucose Tolerance) = Prediabetes
β‰₯ 200 mg/dLDiabetes Mellitus

Why is OGTT used?

  • Better than FPG for detecting early Type 2 DM
  • Essential for diagnosing Gestational Diabetes Mellitus (GDM)
  • Reveals glucose regulation under physiological stress (a real meal)
For GDM (pregnancy): Different protocol:
  • 2-step approach (USA): 50g glucose screen at 24-28 weeks β†’ if β‰₯130-140 mg/dL at 1hr β†’ do 100g 3-hr OGTT
  • 1-step approach (international): 75g OGTT directly; GDM if fasting β‰₯92, 1-hr β‰₯180, 2-hr β‰₯153 mg/dL

PART 10: HbA1c (GLYCATED HEMOGLOBIN)

What is HbA1c?

When glucose is floating around in your blood at high levels, it spontaneously attaches to proteins in a non-enzymatic process called glycation. HbA1c is formed when glucose attaches to the N-terminal valine of the Ξ²-chain of hemoglobin (specifically the NHβ‚‚ group).
High blood glucose + Hemoglobin A
      ↓ (non-enzymatic, irreversible, SLOW process)
Schiff base (unstable)
      ↓ Amadori rearrangement
HbA1c (stable ketoamine)

Why does HbA1c reflect 3-month glucose control?

  • RBCs (red blood cells) live for approximately 120 days (3 months)
  • As the RBC is born, it has zero HbA1c
  • Every day it lives, more glucose attaches to hemoglobin
  • The amount of HbA1c at the end reflects the average glucose the RBC has been exposed to over its entire lifetime
  • HbA1c is a "memory" of blood glucose for the past 2-3 months
  • It reflects the last 30 days more heavily than earlier months (because younger RBCs are more abundant)

Reference Values

HbA1cInterpretation
< 5.7%Normal
5.7 - 6.4%Prediabetes
β‰₯ 6.5%Diabetes mellitus (diagnostic)
Target < 7%Diabetic treatment goal (ADA guideline)
> 8%Poor control, risk of complications

How HbA1c Correlates to Average Blood Glucose

HbA1cEstimated Average Glucose (eAG)
6%126 mg/dL
7%154 mg/dL
8%183 mg/dL
9%212 mg/dL
10%240 mg/dL

Conditions That Falsely Alter HbA1c

ConditionEffect on HbA1cReason
Hemolytic anemia↓ False lowRBCs destroyed faster β†’ less time for glycation
Iron deficiency anemia↑ False highRBCs live longer β†’ more time for glycation
Hemoglobin variants (HbS, HbC, HbE)UnreliableInterfere with assay
Pregnancy (2nd/3rd trimester)↓ False lowIncreased RBC turnover
Blood transfusion↓ False lowDilutes patient's own RBCs
High-dose vitamin C/E↓ False lowInhibit glycation
In conditions with abnormal RBC turnover β†’ use fructosamine (glycated albumin, reflects 2-3 week average) or OGTT instead.

PART 11: METABOLISM OF INSULIN, GLUCAGON, AND SOMATOSTATIN

Insulin Metabolism

Secretion

  • Normal fasting insulin: 5-15 ΞΌU/mL (35-105 pmol/L)
  • After a meal: peaks at 50-100 ΞΌU/mL
  • Daily secretion: ~40-50 units/day

Half-Life

  • ~5-8 minutes in circulation (very short!)

Degradation

  1. Liver - most important site (~50% of portal insulin removed in FIRST PASS through liver before it even reaches systemic circulation)
  2. Kidneys - second most important (~30-40% of peripheral insulin)
  3. Muscle, adipose - minor

Mechanism of Degradation

  • Insulin-degrading enzyme (IDE) = insulysin - a zinc metalloprotease
  • IDE degrades insulin in the cytosol after receptor-mediated endocytosis
  • Also, insulin-receptor complex is internalized β†’ insulin degraded in lysosomes β†’ receptor recycled to surface

Why does this matter clinically?

  • Kidney disease β†’ insulin half-life prolonged β†’ LESS insulin needed (risk of hypoglycemia)
  • Liver disease β†’ reduced first-pass extraction β†’ HIGHER systemic insulin levels

Glucagon Metabolism

Secretion

  • Normal fasting glucagon: 75-150 pg/mL
  • After protein meal: rises significantly
  • During hypoglycemia: rises markedly (key counter-regulatory response)

Half-Life

  • 3-6 minutes (even shorter than insulin)

Degradation

  • Liver is the primary site (60% removed in first pass)
  • Kidneys are secondary
  • Mechanism: Proteolytic degradation by liver enzymes + renal clearance
  • This rapid degradation means glucagon works quickly but briefly - perfect for the acute hypoglycemia response

Somatostatin Metabolism

Secretion

  • SS-14 predominates in pancreatic Ξ΄ cells
  • SS-28 predominates in intestinal D cells and hypothalamus

Half-Life

  • Remarkably short: 1-3 minutes
  • This is why it mainly acts locally (paracrine) rather than as a true circulating hormone

Degradation

  • Peptidases in plasma (mainly endopeptidases)
  • Liver and kidney clearance
  • Clinical consequence: The natural hormone is useless therapeutically β†’ synthetic analogs needed:
    • Octreotide (tΒ½ ~1.5 hours, SubQ injection 3x/day)
    • Lanreotide (depot injection, monthly)
    • Pasireotide (broader SSTR subtype binding, used in Cushing's)

QUICK REFERENCE SUMMARY TABLE

HormoneMade byChemical natureReceptor typeHalf-lifeMain action
CortisolAdrenal zona fasciculataSteroid (C21)Nuclear60-90 minGluconeogenesis, anti-inflammatory
AldosteroneAdrenal zona glomerulosaSteroid (C21)Nuclear15-20 minNa⁺ retention, K⁺ excretion
TestosteroneTestes (Leydig cells)Steroid (C19)Nuclear2-4 hoursVirilization, anabolism
EstradiolOvaries (granulosa)Steroid (C18)Nuclear1-2 hoursFemale reproductive
T4 (Thyroxine)Thyroid follicular cellsIodinated amino acidNuclear (after β†’ T3)6-7 daysMetabolic rate (prohormone)
T3Peripheral conversionIodinated amino acidNuclear18 hoursMetabolic rate (active)
PTHParathyroid chief cellsPolypeptide (84 AA)GPCR (Gs+Gq)2-4 minRaise blood calcium
InsulinPancreatic Ξ² cellsPolypeptide (51 AA)Receptor tyrosine kinase5-8 minLower blood glucose, anabolic
GlucagonPancreatic Ξ± cellsPolypeptide (29 AA)GPCR (Gs β†’ cAMP)3-6 minRaise blood glucose, catabolic
SomatostatinPancreatic Ξ΄ cellsCyclic peptide (14 or 28 AA)GPCR (Gi β†’ ↓cAMP)1-3 minInhibit insulin, glucagon, GH

Key Concepts to Always Remember

  1. All steroid hormones come from cholesterol; the rate-limiting step is StAR protein moving cholesterol into mitochondria.
  2. Thyroid hormone synthesis needs iodine + TPO enzyme; T4 is a prohormone, T3 is active.
  3. TSH is the most sensitive thyroid test; low TSH = overactive gland, high TSH = underactive gland.
  4. PTH raises calcium AND lowers phosphate; Vitamin D raises both.
  5. Insulin is made as preproinsulin β†’ proinsulin β†’ insulin + C-peptide (released in equal amounts).
  6. GLUT2 is the glucose sensor in Ξ² cells (low affinity, high capacity); GLUT4 is insulin-regulated in muscle/fat.
  7. C-peptide helps distinguish endogenous insulin production from exogenous injection.
  8. HbA1c reflects average blood glucose over 120 days (RBC lifespan); β‰₯6.5% = diabetes.
  9. Glucagon β†’ GPCR β†’ cAMP β†’ PKA β†’ glycogenolysis + gluconeogenesis.
  10. Somatostatin = master inhibitor of both insulin and glucagon via Gi β†’ ↓cAMP pathway; half-life 1-3 minutes.

Sources: Guyton & Hall Textbook of Medical Physiology 14e; Basic Medical Biochemistry 6e; Harper's Illustrated Biochemistry 32e; Ganong's Review of Medical Physiology 26e; Tietz Textbook of Laboratory Medicine 7e; Harrison's Principles of Internal Medicine 22e; Costanzo Physiology 7e; Robbins & Kumar Basic Pathology; Quick Compendium of Clinical Pathology 5e

Make a presentation on clinical diagnosis and management of thyroid disorders step-by-step

Reading File
Reading File
Reading File
Reading File
Running Command

ls /home/daytona/workspace/ 2>/dev/null && mkdir -p /home/daytona/workspace/thyr…

Writing File

~/thyroid-pptx/build.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE";
pres.title = "Clinical Diagnosis & Management of Thyroid Disorders";
pres.author = "Medical Biochemistry";

// ── Palette ──────────────────────────────────────────────────────────────────
const C = {
  navy:    "0D2B55",   // dominant dark
  teal:    "0F7D8C",   // accent 1
  sky:     "38B2C0",   // accent 2 (lighter)
  mint:    "D0F0F4",   // light bg tint
  amber:   "E8963A",   // warm accent / highlight
  white:   "FFFFFF",
  offWhite:"F5F8FA",
  text:    "1A2E3F",
  sub:     "4A6578",
  lightGray:"E2E8F0",
  red:     "D94F4F",
  green:   "2D9B5A",
  orange:  "E07A2F",
};

// ── Shared Helpers ────────────────────────────────────────────────────────────
function darkSlide(slide) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:13.3, h:7.5, fill:{ color: C.navy }, line:{ color: C.navy } });
}
function accentBar(slide, color=C.teal, h=0.08) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:7.42-h, w:13.3, h:h+0.1, fill:{ color: color }, line:{ color: color } });
}
function sectionHeader(slide, title, sub="") {
  darkSlide(slide);
  // left teal bar
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.4, h:7.5, fill:{ color: C.teal }, line:{ color: C.teal } });
  slide.addText(title, { x:0.7, y:2.5, w:11.5, h:1.3, fontSize:40, bold:true, color:C.white, fontFace:"Calibri Light" });
  if (sub) slide.addText(sub, { x:0.7, y:3.85, w:11.5, h:0.8, fontSize:20, color:C.sky, fontFace:"Calibri" });
  accentBar(slide, C.amber);
}
function contentSlide(slide) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:13.3, h:7.5, fill:{ color: C.offWhite }, line:{ color: C.offWhite } });
  accentBar(slide, C.teal);
}
function slideTitle(slide, title, x=0.4, y=0.22, w=12.5, h=0.7) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:13.3, h:1.0, fill:{ color: C.navy }, line:{ color: C.navy } });
  slide.addText(title, { x, y, w, h, fontSize:26, bold:true, color:C.white, fontFace:"Calibri Light", valign:"middle", margin:0 });
}
function pillBadge(slide, text, x, y, w, bgColor=C.teal) {
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, { x, y, w, h:0.38, fill:{ color: bgColor }, line:{ color: bgColor }, rectRadius:0.15 });
  slide.addText(text, { x, y, w, h:0.38, fontSize:12, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
}
function card(slide, x, y, w, h, fill=C.white) {
  slide.addShape(pres.shapes.RECTANGLE, { x, y, w, h, fill:{ color: fill }, line:{ color: C.lightGray }, shadow:{ type:"outer", color:"000000", blur:5, offset:2, angle:135, opacity:0.10 } });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 1 β€” TITLE
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  darkSlide(s);
  // gradient-like overlay strip
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:5.5, h:7.5, fill:{ color: C.teal }, line:{ color: C.teal }, transparency:75 });
  s.addText("CLINICAL DIAGNOSIS &\nMANAGEMENT OF", {
    x:0.7, y:1.2, w:11.5, h:1.6, fontSize:34, bold:true, color:C.sky,
    fontFace:"Calibri Light", charSpacing:2
  });
  s.addText("THYROID DISORDERS", {
    x:0.7, y:2.65, w:11.5, h:1.6, fontSize:52, bold:true, color:C.white,
    fontFace:"Calibri Light"
  });
  s.addText("A Step-by-Step Clinical Guide", {
    x:0.7, y:4.35, w:8, h:0.55, fontSize:20, color:C.mint, fontFace:"Calibri", italic:true
  });
  s.addShape(pres.shapes.RECTANGLE, { x:0.7, y:5.1, w:2.5, h:0.06, fill:{ color: C.amber }, line:{ color: C.amber } });
  s.addText("Topics: Hypothyroidism β€’ Hyperthyroidism β€’ Goiter β€’ Thyroid Nodules β€’ Thyroid Cancer", {
    x:0.7, y:5.3, w:11.5, h:0.5, fontSize:14, color:C.mint, fontFace:"Calibri"
  });
  accentBar(s, C.amber);
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 2 β€” OVERVIEW / TABLE OF CONTENTS
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "What We Will Cover");
  const topics = [
    ["01", "HPT Axis & Thyroid Physiology Review", C.teal],
    ["02", "Step-by-Step Diagnostic Approach", C.navy],
    ["03", "Hypothyroidism – Diagnosis & Management", C.teal],
    ["04", "Hyperthyroidism – Diagnosis & Management", C.navy],
    ["05", "Goiter & Thyroid Nodules", C.teal],
    ["06", "Thyroid Cancer – Diagnosis & Management", C.navy],
    ["07", "Special Situations (Pregnancy, Subclinical)", C.teal],
    ["08", "Key Laboratory Reference Values", C.navy],
  ];
  const col1 = topics.slice(0,4);
  const col2 = topics.slice(4);
  col1.forEach(([num,title,col],i)=>{
    const y = 1.3 + i*1.35;
    card(s, 0.35, y, 5.9, 1.15, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x:0.35, y, w:0.7, h:1.15, fill:{ color:col }, line:{ color:col } });
    s.addText(num, { x:0.35, y, w:0.7, h:1.15, fontSize:22, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri Light" });
    s.addText(title, { x:1.15, y:y+0.28, w:5.0, h:0.6, fontSize:14, bold:true, color:C.text, fontFace:"Calibri", valign:"middle" });
  });
  col2.forEach(([num,title,col],i)=>{
    const y = 1.3 + i*1.35;
    card(s, 6.85, y, 6.0, 1.15, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x:6.85, y, w:0.7, h:1.15, fill:{ color:col }, line:{ color:col } });
    s.addText(num, { x:6.85, y, w:0.7, h:1.15, fontSize:22, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri Light" });
    s.addText(title, { x:7.65, y:y+0.28, w:5.0, h:0.6, fontSize:14, bold:true, color:C.text, fontFace:"Calibri", valign:"middle" });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 3 β€” SECTION: PHYSIOLOGY
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 1: PHYSIOLOGY", "HPT Axis – The Foundation of Thyroid Diagnostics");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 4 β€” HPT AXIS
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "The HPT Axis – How the Thyroid is Controlled");

  // Flow boxes
  const boxes = [
    { label:"Hypothalamus", sub:"Releases TRH\n(Thyrotropin-releasing\nhormone – tripeptide)", x:0.4, col:C.navy },
    { label:"Anterior Pituitary", sub:"Releases TSH\n(Thyroid-stimulating\nhormone – glycoprotein)", x:3.9, col:C.teal },
    { label:"Thyroid Gland", sub:"Produces T4 (80%)\nand T3 (20%)\nvia NIS + TPO", x:7.4, col:C.sky },
    { label:"Target Tissues", sub:"T4 β†’ T3 conversion\n(liver, kidney, muscle)\nActive T3 acts on nucleus", x:10.1, col:C.amber },
  ];
  boxes.forEach(b=>{
    card(s, b.x, 1.3, 2.9, 3.6, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x:b.x, y:1.3, w:2.9, h:0.55, fill:{ color:b.col }, line:{ color:b.col } });
    s.addText(b.label, { x:b.x, y:1.3, w:2.9, h:0.55, fontSize:14, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
    s.addText(b.sub, { x:b.x+0.1, y:2.0, w:2.7, h:2.8, fontSize:13, color:C.text, fontFace:"Calibri", valign:"top", lineSpacingMultiple:1.3 });
  });
  // arrows
  ["3.35","6.85","10.38"].forEach((ax,i)=>{
    s.addShape(pres.shapes.RIGHT_ARROW, { x:parseFloat(ax), y:2.8, w:0.5, h:0.4, fill:{ color:C.teal }, line:{ color:C.teal } });
  });

  // Negative feedback label
  s.addShape(pres.shapes.RECTANGLE, { x:0.4, y:5.2, w:12.5, h:0.65, fill:{ color:C.mint }, line:{ color:C.sky } });
  s.addText("NEGATIVE FEEDBACK: Free T3/T4 suppress both TRH (hypothalamus) and TSH (pituitary) β€” this forms the basis of ALL thyroid function tests", {
    x:0.55, y:5.22, w:12.2, h:0.6, fontSize:12.5, color:C.teal, bold:true, fontFace:"Calibri", valign:"middle"
  });
  s.addText("Key Principle: TSH has a LOGARITHMIC inverse relationship with free T4 β€” a tiny drop in FT4 causes a LARGE surge in TSH, making TSH the most sensitive test.", {
    x:0.4, y:6.05, w:12.5, h:0.55, fontSize:12, color:C.sub, fontFace:"Calibri", italic:true
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 5 β€” SECTION: DIAGNOSTIC APPROACH
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 2: DIAGNOSTIC APPROACH", "Step-by-step framework for any thyroid presentation");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 6 β€” STEP-BY-STEP DIAGNOSTIC ALGORITHM
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Step-by-Step Diagnostic Algorithm");

  const steps = [
    { n:"1", title:"History & Physical Exam", body:"Symptoms: weight change, palpitations, fatigue, heat/cold intolerance\nNeck: goiter, nodule, tenderness | Family history | Drug history (amiodarone, lithium, immunotherapy)", col:C.navy },
    { n:"2", title:"Screen with TSH (3rd-gen assay)", body:"TSH normal β†’ euthyroid (no further testing in stable outpatient)\nTSH low β†’ suspect hyperthyroidism β†’ add FT4 + FT3\nTSH high β†’ suspect hypothyroidism β†’ add FT4", col:C.teal },
    { n:"3", title:"Confirm with Free T4 (Β± Free T3)", body:"FT4 low + TSH high β†’ Primary hypothyroidism\nFT4 high + TSH low β†’ Primary hyperthyroidism\nFT4 low + TSH low β†’ Central (pituitary) hypothyroidism", col:C.navy },
    { n:"4", title:"Identify Etiology (Cause)", body:"Anti-TPO antibodies β†’ Hashimoto's or Graves'\nTSI (thyroid-stimulating immunoglobulin) β†’ Graves' disease\nRAIU scan β†’ Graves' vs. toxic nodule vs. thyroiditis\nUltrasound β†’ structural: nodule, goiter, cancer risk", col:C.teal },
    { n:"5", title:"Classify & Manage", body:"Primary / Secondary / Subclinical? Overt vs. borderline?\nInitiate treatment based on type (see following slides)\nMonitor response: TSH every 6-8 weeks after any dose change", col:C.amber },
  ];

  steps.forEach((st,i)=>{
    const y = 1.15 + i*1.21;
    card(s, 0.35, y, 12.6, 1.1, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x:0.35, y, w:0.65, h:1.1, fill:{ color:st.col }, line:{ color:st.col } });
    s.addText(st.n, { x:0.35, y, w:0.65, h:1.1, fontSize:20, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri Light" });
    s.addText("STEP "+st.n+": "+st.title, { x:1.1, y:y+0.05, w:4.2, h:0.45, fontSize:13, bold:true, color:st.col, fontFace:"Calibri", valign:"middle" });
    s.addText(st.body, { x:1.1, y:y+0.5, w:11.7, h:0.55, fontSize:11.5, color:C.text, fontFace:"Calibri", valign:"top" });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 7 β€” SECTION: HYPOTHYROIDISM
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 3: HYPOTHYROIDISM", "Deficiency of thyroid hormones β€” the most common thyroid disorder");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 8 β€” HYPOTHYROIDISM CAUSES & CLINICAL FEATURES
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Hypothyroidism β€” Causes & Clinical Features");

  // LEFT PANEL: Causes
  card(s, 0.35, 1.15, 4.2, 5.8, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:1.15, w:4.2, h:0.55, fill:{ color:C.navy }, line:{ color:C.navy } });
  s.addText("CAUSES", { x:0.35, y:1.15, w:4.2, h:0.55, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
  const causes = [
    ["Primary (most common)",""],
    ["Hashimoto's thyroiditis","Autoimmune (anti-TPO +)"],
    ["Post-radioiodine / surgery","Iatrogenic"],
    ["Iodine deficiency","Worldwide #1 cause"],
    ["Drugs","Amiodarone, lithium, PTU excess, immune checkpoint inhibitors"],
    ["Congenital hypothyroidism","Absent gland / TPO defect"],
    ["",""],
    ["Secondary (central)",""],
    ["Pituitary adenoma","Low TSH + Low FT4"],
    ["Sheehan's syndrome","Post-partum pituitary necrosis"],
  ];
  causes.forEach((c,i)=>{
    if(c[0]==="Primary (most common)" || c[0]==="Secondary (central)") {
      s.addText(c[0], { x:0.5, y:1.82+i*0.48, w:3.9, h:0.38, fontSize:11.5, bold:true, color:C.teal, fontFace:"Calibri" });
    } else if(c[0]==="") {
      // spacer
    } else {
      s.addText("β€’ "+c[0], { x:0.55, y:1.82+i*0.48, w:2.4, h:0.38, fontSize:11, color:C.text, fontFace:"Calibri", valign:"middle" });
      if(c[1]) s.addText(c[1], { x:2.95, y:1.82+i*0.48, w:1.5, h:0.38, fontSize:9.5, color:C.sub, fontFace:"Calibri", italic:true, valign:"middle" });
    }
  });

  // RIGHT PANEL: Symptoms
  card(s, 4.85, 1.15, 8.1, 5.8, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:4.85, y:1.15, w:8.1, h:0.55, fill:{ color:C.teal }, line:{ color:C.teal } });
  s.addText("CLINICAL FEATURES (Myxedema Symptoms)", { x:4.85, y:1.15, w:8.1, h:0.55, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });

  const systems = [
    { sys:"General", sx:"Weight gain, cold intolerance, fatigue, lethargy", x:5.05, y:1.85 },
    { sys:"Skin", sx:"Dry, coarse skin; puffy face (periorbital edema); non-pitting edema; alopecia; brittle nails", x:5.05, y:2.45 },
    { sys:"CVS", sx:"Bradycardia, reduced cardiac output, pericardial effusion, hypertension", x:5.05, y:3.1 },
    { sys:"Neuro", sx:"Slowed reflexes (delayed relaxation), cognitive slowing, depression, carpal tunnel syndrome", x:5.05, y:3.75 },
    { sys:"GI", sx:"Constipation, macroglossia, abdominal distension", x:5.05, y:4.38 },
    { sys:"Repro", sx:"Menorrhagia, anovulation, infertility; galactorrhea (↑TRH β†’ ↑prolactin)", x:5.05, y:4.95 },
    { sys:"Labs", sx:"↑TSH, ↓FT4, ↑cholesterol, ↑CK, hyponatremia, normocytic or macrocytic anemia", x:5.05, y:5.55 },
  ];
  systems.forEach(({sys,sx,x,y})=>{
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x, y, w:1.3, h:0.42, fill:{ color:C.navy }, line:{ color:C.navy }, rectRadius:0.08 });
    s.addText(sys, { x, y, w:1.3, h:0.42, fontSize:11, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
    s.addText(sx, { x:x+1.4, y:y+0.02, w:6.4, h:0.4, fontSize:11, color:C.text, fontFace:"Calibri", valign:"middle" });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 9 β€” HYPOTHYROIDISM DIAGNOSIS & MANAGEMENT
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Hypothyroidism β€” Diagnosis & Management");

  // DIAGNOSIS
  card(s, 0.35, 1.15, 5.9, 2.9, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:1.15, w:5.9, h:0.5, fill:{ color:C.navy }, line:{ color:C.navy } });
  s.addText("DIAGNOSIS", { x:0.35, y:1.15, w:5.9, h:0.5, fontSize:16, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const diag = [
    "TSH > 5.0 mIU/L = hypothyroid; confirm with FT4",
    "Overt hypothyroidism: TSH ↑ + FT4 ↓",
    "Subclinical hypothyroidism: TSH ↑ (5–10) + FT4 normal",
    "Central hypothyroid: TSH low/normal + FT4 ↓ (pituitary disease)",
    "Anti-TPO antibodies positive β†’ Hashimoto's",
  ];
  diag.forEach((d,i)=>{
    s.addText("β€’ "+d, { x:0.55, y:1.78+i*0.44, w:5.6, h:0.4, fontSize:11.5, color:C.text, fontFace:"Calibri", valign:"middle" });
  });

  // LABS
  card(s, 0.35, 4.2, 5.9, 2.65, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:4.2, w:5.9, h:0.5, fill:{ color:C.teal }, line:{ color:C.teal } });
  s.addText("SUPPORTING LABS", { x:0.35, y:4.2, w:5.9, h:0.5, fontSize:16, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const labs = [
    "Lipid panel (hypercholesterolemia common)",
    "CBC (normocytic / macrocytic anemia)",
    "Serum CK (elevated in myxedema)",
    "Thyroid ultrasound if nodule/goiter palpated",
    "Anti-TPO, anti-Tg antibodies",
  ];
  labs.forEach((l,i)=>{
    s.addText("β€’ "+l, { x:0.55, y:4.82+i*0.44, w:5.6, h:0.4, fontSize:11.5, color:C.text, fontFace:"Calibri", valign:"middle" });
  });

  // MANAGEMENT
  card(s, 6.55, 1.15, 6.4, 5.7, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:6.55, y:1.15, w:6.4, h:0.5, fill:{ color:C.amber }, line:{ color:C.amber } });
  s.addText("MANAGEMENT", { x:6.55, y:1.15, w:6.4, h:0.5, fontSize:16, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const mgmt = [
    ["Drug of Choice:", "Levothyroxine (LT4) – synthetic T4"],
    ["Starting Dose:", "1.6 ΞΌg/kg/day (full replacement)\nElderly/cardiac: start 25-50 ΞΌg/day, titrate slowly"],
    ["Monitoring:", "Check TSH every 6-8 weeks after ANY dose change\nTarget TSH: 0.5–2.5 mIU/L (younger patients)\nTarget TSH: 1–4 mIU/L (elderly, pregnancy: 0.1–2.5)"],
    ["Administration:", "Take on empty stomach, 30–60 min before food\nAvoid: calcium, iron, PPIs within 4 hours"],
    ["Subclinical:", "Treat if TSH > 10 OR if TSH 5–10 with symptoms,\npregnancy, anti-TPO positive"],
    ["Emergency:", "Myxedema coma: IV T4 200–400 ΞΌg stat + IV T3\n+ hydrocortisone (rule out adrenal crisis)"],
  ];
  mgmt.forEach(([lbl,txt],i)=>{
    s.addText(lbl, { x:6.75, y:1.78+i*0.9, w:1.9, h:0.35, fontSize:11.5, bold:true, color:C.amber, fontFace:"Calibri", valign:"middle" });
    s.addText(txt, { x:8.7, y:1.78+i*0.9, w:4.1, h:0.75, fontSize:11, color:C.text, fontFace:"Calibri", valign:"top", lineSpacingMultiple:1.2 });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 10 β€” SECTION: HYPERTHYROIDISM
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 4: HYPERTHYROIDISM", "Excess thyroid hormone β€” a hypermetabolic state");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 11 β€” HYPERTHYROIDISM CAUSES & CLINICAL FEATURES
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Hyperthyroidism β€” Causes & Clinical Features");

  card(s, 0.35, 1.15, 4.2, 5.8, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:1.15, w:4.2, h:0.55, fill:{ color:C.red }, line:{ color:C.red } });
  s.addText("CAUSES", { x:0.35, y:1.15, w:4.2, h:0.55, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const hCauses = [
    ["Graves' Disease","Most common (70–80%)"],
    ["Toxic Multinodular Goiter","Middle-aged/elderly"],
    ["Toxic Adenoma","Single autonomous nodule"],
    ["Subacute thyroiditis","Painful, post-viral (de Quervain)"],
    ["Hashitoxicosis","Early Hashimoto's"],
    ["Exogenous T4/T3","Factitious hyperthyroidism"],
    ["TSH-secreting pituitary tumor","TSH ↑ + FT4 ↑ (rare)"],
    ["Struma ovarii","Ectopic thyroid in ovarian teratoma"],
  ];
  hCauses.forEach(([cause,note],i)=>{
    s.addText("β€’ "+cause, { x:0.5, y:1.85+i*0.58, w:2.2, h:0.48, fontSize:11, color:C.text, bold:true, fontFace:"Calibri", valign:"middle" });
    s.addText(note, { x:2.75, y:1.85+i*0.58, w:1.7, h:0.48, fontSize:10, color:C.sub, fontFace:"Calibri", italic:true, valign:"middle" });
  });

  card(s, 4.85, 1.15, 8.1, 5.8, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:4.85, y:1.15, w:8.1, h:0.55, fill:{ color:C.red }, line:{ color:C.red } });
  s.addText("CLINICAL FEATURES β€” Thyrotoxicosis", { x:4.85, y:1.15, w:8.1, h:0.55, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const hSx = [
    { sys:"General", sx:"Weight loss despite increased appetite, heat intolerance, sweating, fatigue" },
    { sys:"CVS", sx:"Palpitations, tachycardia (AF common), wide pulse pressure, cardiac failure" },
    { sys:"Neuro", sx:"Anxiety, irritability, tremor (fine), insomnia, hyperreflexia" },
    { sys:"GI", sx:"Diarrhea, hyperdefecation, nausea" },
    { sys:"Musculo", sx:"Proximal myopathy, thyrotoxic periodic paralysis (esp. Asian males)" },
    { sys:"Repro", sx:"Oligomenorrhea, reduced libido, gynaecomastia (males)" },
    { sys:"Eyes", sx:"Graves' ophthalmopathy: proptosis, lid lag, chemosis (TSI-mediated)" },
    { sys:"Neck", sx:"Diffuse goiter (Graves), nodular goiter (TMNG), bruit (Graves)" },
  ];
  hSx.forEach(({sys,sx},i)=>{
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:5.05, y:1.85+i*0.58, w:1.3, h:0.42, fill:{ color:C.red }, line:{ color:C.red }, rectRadius:0.08 });
    s.addText(sys, { x:5.05, y:1.85+i*0.58, w:1.3, h:0.42, fontSize:11, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
    s.addText(sx, { x:6.45, y:1.87+i*0.58, w:6.4, h:0.4, fontSize:11, color:C.text, fontFace:"Calibri", valign:"middle" });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 12 β€” HYPERTHYROIDISM DIAGNOSIS & MANAGEMENT
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Hyperthyroidism β€” Diagnosis & Management");

  card(s, 0.35, 1.15, 5.9, 3.2, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:1.15, w:5.9, h:0.5, fill:{ color:C.navy }, line:{ color:C.navy } });
  s.addText("DIAGNOSIS", { x:0.35, y:1.15, w:5.9, h:0.5, fontSize:16, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const hDiag = [
    "TSH < 0.1 mIU/L (suppressed) + FT4 ↑ = overt hyperthyroidism",
    "TSH low + FT4 normal β†’ check FT3 (T3 toxicosis)",
    "TSI positive β†’ Graves' disease (90% sensitivity)",
    "RAIU ↑ diffuse β†’ Graves' | focal hotspot β†’ Toxic adenoma",
    "RAIU ↓ β†’ Thyroiditis | Exogenous T4 | Struma ovarii",
    "Thyroid ultrasound with Doppler (Graves' β†’ hypervascular)",
  ];
  hDiag.forEach((d,i)=>{
    s.addText("β€’ "+d, { x:0.55, y:1.78+i*0.42, w:5.6, h:0.38, fontSize:11.5, color:C.text, fontFace:"Calibri", valign:"middle" });
  });

  card(s, 0.35, 4.5, 5.9, 2.35, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:4.5, w:5.9, h:0.5, fill:{ color:C.teal }, line:{ color:C.teal } });
  s.addText("GRAVES' DISEASE SPECIFIC", { x:0.35, y:4.5, w:5.9, h:0.5, fontSize:16, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
  const gd = [
    "Diffuse goiter + eye signs + pretibial myxedema = classic triad",
    "TSI/TRAb: diagnostic (differentiates from other causes)",
    "First-line: Antithyroid drugs (ATDs) for 12–18 months",
    "Monitor: TRAb levels to predict remission/relapse",
  ];
  gd.forEach((d,i)=>{
    s.addText("β€’ "+d, { x:0.55, y:5.1+i*0.42, w:5.6, h:0.38, fontSize:11.5, color:C.text, fontFace:"Calibri", valign:"middle" });
  });

  card(s, 6.55, 1.15, 6.4, 5.7, C.white);
  s.addShape(pres.shapes.RECTANGLE, { x:6.55, y:1.15, w:6.4, h:0.5, fill:{ color:C.red }, line:{ color:C.red } });
  s.addText("MANAGEMENT β€” 3 Treatment Options", { x:6.55, y:1.15, w:6.4, h:0.5, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });

  const opts = [
    { num:"1", title:"Antithyroid Drugs (ATDs)", body:"Methimazole (preferred) or PTU (pregnancy 1st trim)\nBlocks TPO β†’ stops organification\nDose: Methimazole 10–30 mg/day; PTU 100–300 mg TDS\nSE: agranulocytosis (0.5%), hepatotoxicity (PTU)\nMonitor: TFTs every 4–6 weeks; CBC if fever/sore throat", col:C.navy },
    { num:"2", title:"Radioactive Iodine (ΒΉΒ³ΒΉI)", body:"Ablates thyroid tissue β†’ hypothyroidism in 6–12 months\nPreferred in Graves'/TMNG (not pregnancy, severe ophthalmopathy)\nPre-treat with ATDs in severe disease\nPost-treatment: lifelong levothyroxine replacement", col:C.teal },
    { num:"3", title:"Surgery (Thyroidectomy)", body:"Total thyroidectomy for large goiter, cancer risk,\nfailed ATDs, patient preference\nPre-op: render euthyroid with ATDs + iodine (Lugol's)\nComplications: hypoparathyroidism, RLN palsy", col:C.amber },
  ];
  opts.forEach(({num,title,body,col},i)=>{
    const y = 1.8 + i*1.85;
    s.addShape(pres.shapes.RECTANGLE, { x:6.7, y, w:0.6, h:1.6, fill:{ color:col }, line:{ color:col } });
    s.addText(num, { x:6.7, y, w:0.6, h:1.6, fontSize:22, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
    s.addText(title, { x:7.4, y:y+0.05, w:5.4, h:0.4, fontSize:13, bold:true, color:col, fontFace:"Calibri" });
    s.addText(body, { x:7.4, y:y+0.45, w:5.4, h:1.1, fontSize:11, color:C.text, fontFace:"Calibri", valign:"top", lineSpacingMultiple:1.2 });
  });

  // Thyroid storm box
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:6.85, w:12.6, h:0.55, fill:{ color:C.red }, line:{ color:C.red } });
  s.addText("⚠ THYROID STORM: PTU + Propranolol + Lugol's iodine + Dexamethasone + Cooling β€” ICU admission", { x:0.45, y:6.87, w:12.4, h:0.48, fontSize:12.5, bold:true, color:C.white, fontFace:"Calibri", valign:"middle" });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 13 β€” SECTION: GOITER & NODULES
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 5: GOITER & NODULES", "Structural thyroid abnormalities β€” when to investigate");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 14 β€” GOITER & THYROID NODULE EVALUATION
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Thyroid Nodule β€” Step-by-Step Evaluation");

  // Flowchart-style algorithm
  const nodes = [
    { label:"Thyroid Nodule Detected\n(clinical / incidental / US)", x:4.5, y:1.25, w:4.3, h:0.7, fill:C.navy, textColor:C.white, fontSize:13 },
    { label:"Step 1: Check TSH", x:5.0, y:2.2, w:3.3, h:0.55, fill:C.teal, textColor:C.white, fontSize:12 },
    { label:"TSH Low\n(Autonomous nodule?)", x:0.7, y:3.1, w:3.0, h:0.65, fill:C.orange, textColor:C.white, fontSize:11 },
    { label:"TSH Normal/High\n(Most common)", x:9.1, y:3.1, w:3.5, h:0.65, fill:C.teal, textColor:C.white, fontSize:11 },
    { label:"RAIU Scan:\nHot nodule β†’ treat hyper-\nthyroidism (RAI or surgery)", x:0.4, y:4.05, w:3.5, h:0.85, fill:C.white, textColor:C.text, fontSize:10.5 },
    { label:"Step 2: Thyroid Ultrasound\nTIRADS scoring (size, echogenicity,\nmargins, calcification, shape)", x:8.0, y:4.05, w:4.95, h:0.85, fill:C.white, textColor:C.text, fontSize:10.5 },
    { label:"TIRADS 1-2: Benign\nNo biopsy needed\nRoutine follow-up", x:0.4, y:5.15, w:3.5, h:0.85, fill:C.green, textColor:C.white, fontSize:10.5 },
    { label:"TIRADS 3: Low suspicion\nBiopsy if β‰₯2.5 cm\nor growing", x:4.2, y:5.15, w:3.2, h:0.85, fill:C.teal, textColor:C.white, fontSize:10.5 },
    { label:"TIRADS 4-5: High suspicion\nFNA Biopsy regardless\nof size (>1 cm)", x:7.65, y:5.15, w:3.5, h:0.85, fill:C.red, textColor:C.white, fontSize:10.5 },
    { label:"Bethesda Classification (Cytology): I=Non-diagnostic | II=Benign | III/IV=Indeterminate | V=Suspicious | VI=Malignant", x:0.4, y:6.22, w:12.5, h:0.6, fill:C.navy, textColor:C.white, fontSize:11 },
  ];
  nodes.forEach(({label,x,y,w,h,fill,textColor,fontSize})=>{
    card(s, x, y, w, h, fill);
    s.addShape(pres.shapes.RECTANGLE, { x, y, w, h, fill:{ color:fill }, line:{ color:fill } });
    s.addText(label, { x:x+0.06, y, w:w-0.12, h, fontSize, color:textColor, fontFace:"Calibri", align:"center", valign:"middle", lineSpacingMultiple:1.2 });
  });

  // Arrows
  s.addShape(pres.shapes.DOWN_ARROW, { x:6.4, y:1.97, w:0.5, h:0.28, fill:{ color:C.teal }, line:{ color:C.teal } });
  s.addShape(pres.shapes.DOWN_ARROW, { x:2.05, y:3.78, w:0.45, h:0.3, fill:{ color:C.orange }, line:{ color:C.orange } });
  s.addShape(pres.shapes.DOWN_ARROW, { x:10.45, y:3.78, w:0.45, h:0.3, fill:{ color:C.teal }, line:{ color:C.teal } });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 15 β€” SECTION: THYROID CANCER
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 6: THYROID CANCER", "Diagnosis, staging and management of malignant thyroid disease");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 16 β€” THYROID CANCER TYPES & MANAGEMENT
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Thyroid Cancer β€” Types, Diagnosis & Management");

  const types = [
    { name:"Papillary\nThyroid Ca", pct:"85%", origin:"Follicular cells", markers:"Thyroglobulin, BRAF V600E", spread:"Lymph nodes (cervical)", prog:"Excellent (>95% 10-yr survival)", mgmt:"Total thyroidectomy + RAI ablation + TSH suppression with LT4", col:C.teal },
    { name:"Follicular\nThyroid Ca", pct:"10%", origin:"Follicular cells", markers:"Thyroglobulin, RAS mutations", spread:"Hematogenous (lung, bone)", prog:"Good (80% 10-yr survival)", mgmt:"Total thyroidectomy + RAI + TSH suppression", col:C.navy },
    { name:"Medullary\nThyroid Ca", pct:"3-4%", origin:"C-cells (parafollicular)", markers:"Calcitonin, CEA, RET mutation", spread:"Lymph nodes + systemic", prog:"Moderate (75% 10-yr)", mgmt:"Total thyroidectomy (NO RAI β€” calcitonin not iodine-avid)\nVandetanib/Cabozantinib for metastatic", col:C.orange },
    { name:"Anaplastic\nThyroid Ca", pct:"1-2%", origin:"Follicular cells (undifferentiated)", markers:"None specific", spread:"Rapid local + distant", prog:"Very poor (median survival 5 months)", mgmt:"Multimodal: surgery + XRT + Dabrafenib/Trametinib (BRAF+)\nPalliative airway management", col:C.red },
  ];
  types.forEach(({name,pct,origin,markers,spread,prog,mgmt,col},i)=>{
    const x = 0.35 + i*3.24;
    card(s, x, 1.15, 3.1, 5.7, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x, y:1.15, w:3.1, h:0.6, fill:{ color:col }, line:{ color:col } });
    s.addText(name, { x, y:1.15, w:3.1, h:0.6, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
    pillBadge(s, pct+" of cases", x+0.7, 1.87, 1.7, col);
    const rows = [["Origin",origin],["Marker",markers],["Spread",spread],["Prognosis",prog],["Management",mgmt]];
    rows.forEach(([lbl,val],j)=>{
      s.addText(lbl+":", { x:x+0.1, y:2.42+j*0.9, w:1.0, h:0.3, fontSize:10.5, bold:true, color:col, fontFace:"Calibri" });
      s.addText(val, { x:x+0.1, y:2.73+j*0.9, w:2.9, h:0.5, fontSize:10.5, color:C.text, fontFace:"Calibri", lineSpacingMultiple:1.1 });
    });
  });

  s.addText("Post-operative monitoring: Thyroglobulin (PTC/FTC) | Calcitonin (MTC) | Whole-body ΒΉΒ³ΒΉI scan | Neck ultrasound every 6–12 months", {
    x:0.35, y:7.05, w:12.6, h:0.38, fontSize:11.5, color:C.sub, fontFace:"Calibri", italic:true
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 17 β€” SECTION: SPECIAL SITUATIONS
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  sectionHeader(s, "PART 7: SPECIAL SITUATIONS", "Subclinical thyroid disease β€’ Pregnancy β€’ Euthyroid sick syndrome");
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 18 β€” SPECIAL CLINICAL SITUATIONS
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Special Clinical Situations");

  const panels = [
    { title:"Subclinical Hypothyroidism", col:C.navy, content:[
      "TSH 5–10 mIU/L, FT4 NORMAL",
      "Treat if: TSH >10, OR symptomatic,\nOR anti-TPO positive, OR pregnant",
      "Start low-dose LT4 (25–50 ΞΌg/day)",
      "Risk if untreated: cardiovascular disease, progression to overt hypothyroidism (4–8%/yr)",
    ]},
    { title:"Subclinical Hyperthyroidism", col:C.red, content:[
      "TSH <0.1 mIU/L, FT4 NORMAL",
      "Treat if: TSH <0.1 + age >65 + cardiac arrhythmia/osteoporosis",
      "TSH 0.1–0.5 (mild): usually monitor",
      "Risk if untreated: AF (3Γ— risk), bone loss",
    ]},
    { title:"Thyroid in Pregnancy", col:C.teal, content:[
      "TSH targets (trimester-specific):\n1st: 0.1–2.5 | 2nd: 0.2–3.0 | 3rd: 0.3–3.0 mIU/L",
      "↑ LT4 dose by 20–30% in pregnancy (↑TBG + fetal demand)",
      "Hyperthyroidism: PTU in 1st trim; Methimazole from 2nd trim",
      "Screen all pregnant women with TSH at booking",
      "Post-partum thyroiditis: hyper phase β†’ hypo phase β†’ recovery",
    ]},
    { title:"Euthyroid Sick Syndrome (NTI)", col:C.orange, content:[
      "Critical illness β†’ ↓T3, ↑rT3, normal/low TSH, normal FT4",
      "NOT true thyroid disease β€” adaptive response",
      "Do NOT initiate thyroid treatment on TFTs alone",
      "Treat underlying illness; TFTs normalize on recovery",
      "If clinical hypothyroidism pre-existing β†’ continue LT4 IV",
    ]},
  ];

  panels.forEach(({title,col,content},i)=>{
    const x = 0.35 + i * 3.24;
    card(s, x, 1.15, 3.1, 5.75, C.white);
    s.addShape(pres.shapes.RECTANGLE, { x, y:1.15, w:3.1, h:0.55, fill:{ color:col }, line:{ color:col } });
    s.addText(title, { x:x+0.05, y:1.15, w:3.0, h:0.55, fontSize:12.5, bold:true, color:C.white, align:"center", valign:"middle", margin:0, fontFace:"Calibri" });
    content.forEach((c,j)=>{
      s.addText("β€’ "+c, { x:x+0.1, y:1.84+j*1.0, w:2.9, h:0.9, fontSize:11, color:C.text, fontFace:"Calibri", valign:"top", lineSpacingMultiple:1.2 });
    });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 19 β€” LABORATORY REFERENCE VALUES
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  contentSlide(s);
  slideTitle(s, "Key Laboratory Reference Values & Interpretation");

  // Table header
  const cols = ["Test","Reference Range","Hypothyroid","Hyperthyroid","Note"];
  const colW = [2.1, 2.3, 1.95, 1.95, 4.6];
  const startX = 0.35;
  let cx = startX;
  cols.forEach((c,i)=>{
    s.addShape(pres.shapes.RECTANGLE, { x:cx, y:1.15, w:colW[i], h:0.5, fill:{ color:C.navy }, line:{ color:C.navy } });
    s.addText(c, { x:cx, y:1.15, w:colW[i], h:0.5, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
    cx += colW[i];
  });

  const rows = [
    ["TSH","0.35–5.0 mIU/L","↑↑ (>10 = overt)","↓↓ (<0.1 = overt)","Most sensitive thyroid test"],
    ["Free T4","12–28 pmol/L","↓","↑","Not affected by TBG changes"],
    ["Free T3","3–9 pmol/L","↓","↑↑","Check if T3 toxicosis suspected"],
    ["Total T4","55–150 nmol/L","↓↓","↑","Affected by TBG (pregnancy ↑, steroids ↓)"],
    ["Total T3","1.5–3.5 nmol/L","↓","↑","T3 toxicosis: T3 ↑ with normal T4"],
    ["rT3",">0.32 nmol/L (if elevated)","↓","normal","↑ in euthyroid sick syndrome"],
    ["Anti-TPO","><35 IU/mL = positive","↑ (Hashimoto's)","↑ (Graves')","Marker of autoimmune thyroid disease"],
    ["TSI","<1.75 IU/L","Negative","↑↑ (Graves')","90% sensitivity for Graves' disease"],
    ["Thyroglobulin","1–25 ng/mL (post-thyroidectomy <1)","Varies","Varies","Post-cancer surveillance marker"],
    ["HbA1c (co-morbidity)","<5.7% normal","Screen for DM in hypothyroid","Screen for DM","Insulin resistance ↑ in both states"],
  ];

  rows.forEach((row,i)=>{
    const rowFill = i%2===0 ? C.white : C.offWhite;
    cx = startX;
    row.forEach((cell,j)=>{
      s.addShape(pres.shapes.RECTANGLE, { x:cx, y:1.65+i*0.54, w:colW[j], h:0.54, fill:{ color:rowFill }, line:{ color:C.lightGray } });
      const textColor = j===2 ? C.red : j===3 ? C.red : C.text;
      s.addText(cell, { x:cx+0.05, y:1.65+i*0.54, w:colW[j]-0.1, h:0.54, fontSize:11, color:textColor, fontFace:"Calibri", valign:"middle", lineSpacingMultiple:1.1 });
      cx += colW[j];
    });
  });
}

// ─────────────────────────────────────────────────────────────────────────────
//  SLIDE 20 β€” SUMMARY / KEY TAKE-AWAYS
// ─────────────────────────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  darkSlide(s);
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.55, h:7.5, fill:{ color:C.amber }, line:{ color:C.amber } });
  s.addText("KEY TAKE-AWAYS", { x:0.75, y:0.35, w:12.0, h:0.75, fontSize:36, bold:true, color:C.white, fontFace:"Calibri Light", charSpacing:3 });
  s.addShape(pres.shapes.RECTANGLE, { x:0.75, y:1.18, w:3.5, h:0.06, fill:{ color:C.amber }, line:{ color:C.amber } });

  const points = [
    "TSH is the FIRST and MOST SENSITIVE test for thyroid function β€” always start here.",
    "Low TSH = hyperthyroid; High TSH = hypothyroid. Central disease (pituitary) breaks this rule β€” check FT4 together.",
    "Hashimoto's (Hypothyroid) = Anti-TPO positive; Graves' (Hyperthyroid) = TSI positive, diffuse goiter, eye signs.",
    "Levothyroxine (LT4) is the drug of choice for hypothyroidism; check TSH every 6-8 weeks after any dose change.",
    "Hyperthyroidism: 3 options β€” ATDs (methimazole), Radioiodine (ΒΉΒ³ΒΉI), or Surgery. Choose based on cause.",
    "All thyroid nodules need TSH + ultrasound (TIRADS) Β± FNA based on size/features β€” Bethesda cytology guides surgery.",
    "Papillary carcinoma (85%) = best prognosis; Anaplastic (1-2%) = worst prognosis. Medullary thyroid Ca monitors calcitonin.",
    "In pregnancy: trim-specific TSH targets; PTU in 1st trimester, methimazole thereafter; increase LT4 dose by 20-30%.",
    "Euthyroid sick syndrome (NTI): ↓T3, ↑rT3 β€” do NOT treat unless true thyroid disease confirmed.",
  ];

  points.forEach((p,i)=>{
    const y = 1.45 + i*0.66;
    s.addShape(pres.shapes.RECTANGLE, { x:0.75, y:y+0.08, w:0.35, h:0.35, fill:{ color:C.amber }, line:{ color:C.amber } });
    s.addText((i+1).toString(), { x:0.75, y:y+0.08, w:0.35, h:0.35, fontSize:12, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
    s.addText(p, { x:1.25, y, w:11.7, h:0.58, fontSize:13, color:C.white, fontFace:"Calibri", valign:"middle", lineSpacingMultiple:1.15 });
  });
  accentBar(s, C.amber);
}

// ─────────────────────────────────────────────────────────────────────────────
//  WRITE FILE
// ─────────────────────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/thyroid-pptx/Thyroid_Disorders_Clinical_Guide.pptx" })
  .then(() => console.log("βœ… Done: Thyroid_Disorders_Clinical_Guide.pptx"))
  .catch(err => { console.error("❌ Error:", err); process.exit(1); });
Running Command

cd /home/daytona/workspace/thyroid-pptx && node build.js 2>&1

Running Command

ls -lh /home/daytona/workspace/thyroid-pptx/Thyroid_Disorders_Clinical_Guide.ppt…

Your presentation is ready! Download it here:

Thyroid Disorders Clinical Guide

Presentation Β· PPTX


What's inside (20 slides, wide 16:9 format)

The deck uses a dark navy + teal + amber color scheme designed specifically for this clinical topic.
SlideContent
1Title slide with topic overview
2Table of Contents (8 parts, card layout)
3Section header - Physiology
4HPT Axis - flow diagram with 4 stations and negative feedback rule
5Section header - Diagnostic Approach
65-Step Diagnostic Algorithm (history β†’ TSH β†’ FT4 β†’ etiology β†’ management)
7Section header - Hypothyroidism
8Hypothyroidism - Causes (Hashimoto's, iatrogenic, drugs, central) + Clinical Features by system
9Hypothyroidism Management - LT4 dosing, targets, monitoring, myxedema coma protocol
10Section header - Hyperthyroidism
11Hyperthyroidism - 8 causes + full system-wise symptoms (tachycardia, tremor, eye signs, etc.)
12Hyperthyroidism Management - Diagnosis, 3 treatment options (ATDs/RAI/Surgery), Graves'-specific, Thyroid Storm box
13Section header - Goiter & Nodules
14Thyroid Nodule Algorithm - TSH β†’ US (TIRADS) β†’ FNA β†’ Bethesda classification flowchart
15Section header - Thyroid Cancer
16Thyroid Cancer - 4 types side-by-side (Papillary/Follicular/Medullary/Anaplastic) with markers, spread, prognosis, management
17Section header - Special Situations
18Special Situations - Subclinical hypo/hyper, Pregnancy (trimester TSH targets), Euthyroid Sick Syndrome
19Laboratory Reference Table - TSH, FT4, FT3, antibodies with normal ranges + hypo/hyper columns
20Key Take-Aways (9 points, dark closing slide)

Make a presentation on clinical diagnosis and management of thyroid disorders step-by-step

Reading File
Running Command

ls -lh /home/daytona/workspace/thyroid-pptx/Thyroid_Disorders_Clinical_Guide.ppt…

The file is already built and ready. Here's your download link:

Thyroid Disorders Clinical Guide

Presentation Β· PPTX


Presentation Overview (20 slides, wide 16:9)

Color scheme: Dark navy dominant, teal accent, amber highlights - designed specifically for clinical medicine.
#SlideKey Content
1TitleFull topic title + subtopics listed
2Table of Contents8 parts shown as numbered cards
3Section breakPhysiology
4HPT Axis4-box flow: Hypothalamus β†’ Pituitary β†’ Thyroid β†’ Tissues + negative feedback rule
5Section breakDiagnostic Approach
65-Step Diagnostic AlgorithmHistory β†’ TSH screen β†’ FT4 confirm β†’ Etiology β†’ Classify & Treat
7Section breakHypothyroidism
8Hypothyroid: Causes & FeaturesHashimoto's, iatrogenic, drugs, central; symptoms by system
9Hypothyroid: Diagnosis & MgmtLT4 dosing, TSH targets, monitoring, myxedema coma
10Section breakHyperthyroidism
11Hyperthyroid: Causes & FeaturesGraves', TMNG, toxic adenoma; symptoms by system incl. eye signs
12Hyperthyroid: Diagnosis & MgmtATDs / Radioiodine / Surgery; Graves'-specific; Thyroid Storm box
13Section breakGoiter & Nodules
14Thyroid Nodule AlgorithmTSH β†’ US TIRADS β†’ FNA β†’ Bethesda cytology flowchart
15Section breakThyroid Cancer
16Thyroid Cancer (4 types)Papillary / Follicular / Medullary / Anaplastic - markers, spread, prognosis, treatment
17Section breakSpecial Situations
18Special SituationsSubclinical hypo/hyper, Pregnancy TSH targets, Euthyroid Sick Syndrome
19Lab Reference TableTSH, FT4, FT3, antibodies - normal ranges + hypo/hyper columns
20Key Take-Aways9 clinical pearls on dark closing slide

u given information first i want that information

You want the detailed biochemistry explanation I gave earlier β€” the full written notes on all the topics. Here it is again, fully reproduced:

🧬 COMPLETE BIOCHEMISTRY GUIDE: Hormones, Metabolism & Diabetes


PART 1: STEROID HORMONE SYNTHESIS

What is a steroid hormone?

Think of steroid hormones as chemical messengers made from cholesterol - the same fat-like molecule that forms your cell membranes. Every single steroid hormone in your body - cortisol, aldosterone, testosterone, estrogen, progesterone - is built from cholesterol. Steroid hormones are lipid-soluble, so they can cross cell membranes directly and act inside the cell (unlike protein hormones that knock on the door from outside).

Where are they made?

Gland/OrganHormones Produced
Adrenal Cortex - Zona FasciculataCortisol
Adrenal Cortex - Zona GlomerulosaAldosterone
Adrenal Cortex - Zona ReticularisDHEA, Androgens
Testes (Leydig cells)Testosterone
Ovaries (Granulosa cells)Estrogen, Progesterone
PlacentaProgesterone, Estriol

The Big Picture Pathway

CHOLESTEROL (C27)
      ↓  [RATE-LIMITING STEP: StAR protein moves cholesterol into mitochondria]
      ↓  [Enzyme: CYP11A1 = P450scc, inner mitochondrial membrane]
PREGNENOLONE  ← "Mother of all steroids"
      ↓  [3Ξ²-HSD enzyme, smooth ER]
PROGESTERONE
      ↓ splits into 3 pathways based on adrenal zone
  β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
  ↓                  ↓                    ↓
GLUCOCORTICOIDS   MINERALOCORTICOIDS   ANDROGENS β†’ ESTROGENS
(Zona Fasciculata) (Zona Glomerulosa)  (Zona Reticularis)
CORTISOL           ALDOSTERONE         DHEA β†’ Testosterone β†’ Estradiol

Step-by-Step Enzymatic Pathway

Step 1 - The Rate-Limiting Step

  • StAR protein (Steroidogenic Acute Regulatory protein) shuttles cholesterol from the outer to the inner mitochondrial membrane
  • ACTH triggers StAR immediately - no StAR = no steroid synthesis
  • Think of StAR as the "gate opener"

Step 2 - Cholesterol β†’ Pregnenolone

  • Enzyme: P450scc (CYP11A1) - "scc" = side chain cleavage
  • Snips off a 6-carbon piece from cholesterol (C27) β†’ pregnenolone (C21)
  • Needs NADPH + Oxygen
  • Location: Inner mitochondrial membrane

Step 3 - Pregnenolone β†’ Progesterone

  • Enzyme: 3Ξ²-HSD + isomerase
  • Converts Ξ”5 compound (pregnenolone) into Ξ”4 compound (progesterone)
  • Location: Smooth ER

Pathway A - CORTISOL (Zona Fasciculata)

Progesterone
  ↓ CYP17A1 (17Ξ±-hydroxylase) β†’ adds OH at C17
17Ξ±-Hydroxyprogesterone (17-OHP)
  ↓ CYP21A2 (21-hydroxylase) β†’ adds OH at C21
11-Deoxycortisol
  ↓ CYP11B1 (11Ξ²-hydroxylase) β†’ adds OH at C11, in mitochondria
CORTISOL βœ“
Exam fact: CYP21A2 deficiency = most common CAH. Can't make cortisol/aldosterone β†’ all precursors flood into androgen pathway β†’ virilization + salt-wasting crisis.

Pathway B - ALDOSTERONE (Zona Glomerulosa)

Progesterone
  ↓ CYP21A2 (21-hydroxylase)
11-Deoxycorticosterone (DOC)
  ↓ CYP11B1 (11Ξ²-hydroxylase)
Corticosterone
  ↓ CYP11B2 (Aldosterone synthase) ← ONLY in zona glomerulosa!
ALDOSTERONE βœ“
Key: Zona glomerulosa lacks CYP17A1 - it's wired only for aldosterone.

Pathway C - ANDROGENS & ESTROGENS

17-Hydroxypregnenolone
  ↓ CYP17A1 (17,20-lyase activity)
DHEA (C19 - weak androgen)
  ↓ 3Ξ²-HSD
Androstenedione
  ↓ 17Ξ²-HSD
TESTOSTERONE (C19)
  ↓ CYP19A1 (Aromatase) in ovarian granulosa cells
ESTRADIOL (C18 - most potent estrogen)

OR
  ↓ 5Ξ±-Reductase in prostate/skin
DHT (most potent androgen, 5Γ— more potent than testosterone)

Carbon Number Rule

  • C21 = Glucocorticoids (cortisol) + Mineralocorticoids (aldosterone) + Progestogens
  • C19 = Androgens (testosterone, DHEA)
  • C18 = Estrogens (estradiol) - have aromatic ring A

Key Enzyme Summary Table

EnzymeGeneLocationReaction
P450scc (side-chain cleavage)CYP11A1MitochondriaCholesterol β†’ Pregnenolone
3Ξ²-HSDHSD3B2Smooth ERPregnenolone β†’ Progesterone
17Ξ±-Hydroxylase / 17,20-lyaseCYP17A1Smooth ER17-OH + androgen pathway
21-HydroxylaseCYP21A2Smooth ER→ Cortisol & Aldosterone pathway
11β-HydroxylaseCYP11B1Mitochondria→ Cortisol
Aldosterone synthaseCYP11B2Mitochondria (ZG only)β†’ Aldosterone
AromataseCYP19A1Smooth ER (ovary, adipose)Androgens β†’ Estrogens
5Ξ±-ReductaseSRD5ATarget tissuesTestosterone β†’ DHT

Regulation

HPA Axis (Glucocorticoids): Stress β†’ Hypothalamus releases CRH β†’ Pituitary releases ACTH β†’ Adrenal makes Cortisol β†’ Cortisol feeds back to inhibit both CRH and ACTH (negative feedback)
RAAS (Aldosterone): Low blood volume β†’ Kidney releases Renin β†’ Angiotensinogen β†’ Angiotensin I β†’ ACE (lung) β†’ Angiotensin II β†’ Stimulates CYP11B2 β†’ Aldosterone production

CAH - Enzyme Deficiency Clinical Table

DeficiencyEffectClinical
21-Hydroxylase (90-95%)↓ Cortisol, ↓ Aldosterone, ↑ AndrogensSalt-wasting crisis + virilization
11Ξ²-Hydroxylase↑ DOC, ↑ Androgens, ↓ CortisolHypertension + virilization
17Ξ±-Hydroxylase↑ Aldosterone, ↓ Cortisol, ↓ AndrogensHypertension + no sexual maturation

PART 2: THYROID HORMONE SYNTHESIS

What are thyroid hormones?

Unlike steroids (made from cholesterol), thyroid hormones are made from tyrosine (an amino acid) + iodine. They regulate your basal metabolic rate - essentially the speed at which every cell in your body runs.
  • T4 (Thyroxine) = 4 iodine atoms, made exclusively in thyroid, is a prohormone (not very active)
  • T3 (Triiodothyronine) = 3 iodine atoms, the active hormone, 80% comes from peripheral conversion of T4
Think of T4 as a "sleeping" version that gets "activated" in tissues by removing one iodine atom.

Where it happens

The thyroid gland is made up of spherical follicles - balloons of cells (thyrocytes) surrounding a jelly-like substance called colloid - which contains thyroglobulin (Tg), a large protein that acts as the scaffold for making T3/T4.

The 6 Steps of Thyroid Hormone Synthesis

Step 1 - Iodide Trapping (Active Transport)

  • Transporter: NIS (Sodium-Iodide Symporter) on the basolateral membrane (blood side)
  • Brings 2 Na⁺ + 1 I⁻ into the cell together (symport)
  • Concentrates iodide 20-40 times higher inside the cell than in blood
  • Driven by the Na⁺ gradient (created by Na/K-ATPase)
  • Pendrin transports I⁻ from cell into the colloid (apical membrane)
  • Regulated by TSH (increases NIS activity); excess iodine inhibits it (Wolff-Chaikoff effect)

Step 2 - Thyroglobulin Synthesis

  • Thyroglobulin (660 kDa glycoprotein) made in rough ER of thyrocyte
  • Processed in Golgi, secreted by exocytosis into the colloid
  • Contains 123 tyrosine residues, but only 4-8 actually become thyroid hormones
  • Think of Tg as a "tyrosine delivery board" waiting to be iodinated

Step 3 - Organification of Iodide

  • Enzyme: TPO (Thyroid Peroxidase) at the apical membrane (colloid side)
  • TPO uses Hβ‚‚Oβ‚‚ (made by DUOX2 enzyme) to oxidize I⁻ β†’ reactive iodine (I⁰)
  • Reactive iodine attaches to tyrosine residues on Tg:
    • One iodine added β†’ MIT (Monoiodotyrosine)
    • Two iodines added β†’ DIT (Diiodotyrosine)
  • Blocked by: PTU, Methimazole (antithyroid drugs)

Step 4 - Coupling (Making T3 and T4)

  • Same enzyme: TPO catalyzes coupling
  • Two iodinated tyrosines join together on the Tg scaffold:
    • DIT + DIT β†’ T4 (thyroxine, 4 iodines) - most abundant
    • MIT + DIT β†’ T3 (3,5,3β€²-triiodothyronine, 3 iodines) - active form
    • DIT + MIT β†’ rT3 (reverse T3, biologically inactive)

Step 5 - Secretion

  1. TSH stimulates thyrocytes to endocytose (eat) the colloid
  2. Colloid vesicles fuse with lysosomes β†’ proteases digest thyroglobulin
  3. Free T4 and T3 released and diffuse into the bloodstream
  4. MIT and DIT are NOT secreted - iodotyrosine deiodinase strips their iodine off and recycles it

Step 6 - Peripheral Conversion (T4 β†’ T3)

  • T4 is a prohormone; must be converted to T3 to be active
  • 80% of circulating T3 comes from this conversion in liver, kidney, muscle
  • Deiodinases contain selenocysteine (selenium):
EnzymeLocationMakes
D1Liver, kidney, thyroidT3 (main circulating T3 source)
D2Brain, pituitary, brown fatLocal T3 (especially in brain/pituitary)
D3Brain, placentaInactive rT3 (inactivates T4)

Transport in Blood

Binding Protein% T4 Bound% T3 Bound
TBG (Thyroxine-binding globulin)67%46%
Transthyretin20%1%
Albumin13%53%
Only the free fraction (0.02% of T4, 0.2% of T3) is biologically active.

Half-Lives

HormoneHalf-Life
T46-7 days
T318 hours

HPT Axis (Regulation)

Hypothalamus β†’ TRH (tripeptide)
      ↓
Anterior Pituitary (thyrotrophs) β†’ TSH (glycoprotein, Ξ±+Ξ² subunits)
      ↓
Thyroid Gland β†’ T4 (mainly) + small T3
      ↑ Negative feedback (free T3/T4 suppress both TRH and TSH)

PART 3: THYROID FUNCTION TESTS

The Tests - One by One

1. TSH (Thyroid-Stimulating Hormone)

  • Normal range: 0.35-5.0 mIU/L
  • The most sensitive test for thyroid dysfunction
  • HIGH TSH = thyroid is failing = Primary Hypothyroidism
  • LOW TSH = thyroid is overactive = Primary Hyperthyroidism
  • Exception: If pituitary is diseased (central hypothyroidism), TSH may be low despite low T4

2. Free T4 (FT4)

  • Normal range: 12-28 pmol/L (0.8-2.4 ng/dL)
  • Measures only the unbound, biologically active T4
  • More reliable than Total T4 because not affected by binding protein changes

3. Free T3 (FT3)

  • Normal range: 3-9 pmol/L
  • Used when: T3 toxicosis suspected (hyperthyroid with normal FT4 but elevated FT3)

4. Total T4 and Total T3

  • Measures bound + free hormone
  • Less useful because binding protein changes confuse results
  • Estrogen (pregnancy, OCP) β†’ ↑TBG β†’ ↑Total T4/T3 (but patient is euthyroid, FT4 normal!)
  • Androgens, glucocorticoids β†’ ↓TBG β†’ ↓Total T4/T3 (still euthyroid)

5. Reverse T3 (rT3)

  • Elevated rT3 + Low T3 + Normal T4 = Euthyroid Sick Syndrome (nonthyroidal illness)
  • In critical illness, starvation, major surgery: body shunts T4 β†’ rT3 (inactive) to conserve energy

6. TRH Stimulation Test

  • Inject 500 ΞΌg TRH IV β†’ measure TSH at 0, 30, 60 min
  • Normal: TSH rises by β‰₯6 mIU/L at 30 min
  • Blunted response: Primary hyperthyroidism OR pituitary disease
  • Exaggerated response: Primary hypothyroidism
  • Largely replaced by modern sensitive TSH assays

7. Thyroid Antibodies

  • Anti-TPO (aTPO): Positive in Hashimoto's (>80%) and Graves'
  • TSI (Thyroid-Stimulating Immunoglobulin): Diagnostic for Graves' disease (~90% sensitivity)
  • Anti-thyroglobulin (ATG): Hashimoto's

Complete Interpretation Table

ConditionTSHFT4FT3
Primary Hyperthyroidism↓↓↑↑
T3 Toxicosis↓Normal↑↑
Subclinical Hyperthyroidism↓NormalNormal
Primary Hypothyroidism↑↑↓↓
Subclinical Hypothyroidism↑NormalNormal
Central (Pituitary) Hypothyroidism↓ or Normal↓↓
Graves' Disease↓↑↑
Euthyroid Sick SyndromeVariable ↓↓↓↓
Pregnancy (↑TBG)NormalNormal FT4Total T4 ↑↑
Hashimoto's Thyroiditis↑↓ or Normal↓ or Normal

PART 4: PTH AND CALCIUM METABOLISM

Why is calcium important?

Calcium is required for:
  • Muscle contraction (including heart muscle)
  • Nerve impulse transmission
  • Blood clotting (coagulation cascade)
  • Cell signaling (second messenger)
  • Enzyme activation
Normal blood calcium: 8.5-10.5 mg/dL (2.1-2.6 mmol/L)

Three Hormones Control Calcium

  1. PTH (Parathyroid Hormone) - raises calcium
  2. Calcitriol (1,25-(OH)β‚‚-Vitamin D) - raises calcium
  3. Calcitonin - lowers calcium (minor role in adults)

PTH Structure and Trigger

  • 84 amino acid polypeptide made by chief cells of the 4 parathyroid glands
  • Biologically active portion = first 34 amino acids (N-terminal)
  • CaSR (Calcium-Sensing Receptor) on chief cells detects blood calcium:
    • Low Ca²⁺ β†’ CaSR inactive β†’ PTH released
    • High Ca²⁺ β†’ CaSR activated β†’ PTH suppressed

PTH's 3 Target Actions

TargetActionEffect
BoneActivates osteoclasts (bone breakers)Releases Ca²⁺ AND PO₄³⁻ from bone
Kidney (DCT)↑ Ca²⁺ reabsorption; ↓ PO₄³⁻ reabsorption (phosphaturic effect)Saves Ca²⁺, loses PO₄³⁻
Kidney (PCT)Activates 1Ξ±-hydroxylase β†’ converts 25-OH-Vit D to CalcitriolIndirectly ↑ intestinal Ca²⁺ absorption
Key point: PTH raises calcium but LOWERS phosphate. So in hyperparathyroidism: Ca²⁺ ↑, POβ‚„ ↓.

PTH Mechanism of Action

  • PTH receptor (PTH1R) is a GPCR
  • PTH β†’ GΞ±s β†’ Adenylyl cyclase β†’ cAMP ↑ β†’ PKA activation
  • Also activates Gq β†’ PLC β†’ IP₃ β†’ Ca²⁺ release + PKC

Vitamin D Activation Pathway

Skin: UV light + 7-dehydrocholesterol β†’ Cholecalciferol (Vitamin D3)
  ↓ Liver: 25-hydroxylase
25-hydroxyvitamin D (Calcidiol) ← what you measure in blood tests!
  ↓ Kidney: 1Ξ±-hydroxylase (activated by PTH, low POβ‚„, low Ca)
1,25-dihydroxyvitamin D (Calcitriol) ← the ACTIVE form

Actions of Calcitriol

  • Intestine: Increases calbindin-D (calcium transport protein) + TRPV6 channels β†’ ↑ Ca²⁺ absorption (up to 80% of dietary calcium)
  • Bone: At normal levels, promotes mineralization; at high levels, releases Ca with PTH
  • Kidney: Mild increase in Ca²⁺ reabsorption
  • Parathyroid gland: Suppresses PTH synthesis (negative feedback)

Calcitonin

  • Made by C-cells (parafollicular cells) of the thyroid
  • Released when Ca²⁺ is HIGH
  • Inhibits osteoclasts β†’ reduces bone resorption; increases renal Ca excretion

Calcium and Phosphate Inverse Relationship

ConditionCalciumPhosphate
Hyperparathyroidism↑↓
Hypoparathyroidism↓↑
Vitamin D toxicity↑↑
CKD↓↑↑ (Secondary hyperparathyroidism)

Phosphate Regulation

HormoneEffect on Blood PhosphateMechanism
PTH↓ (phosphaturia)Inhibits NaPi cotransporter in kidney PCT
Calcitriol↑Increases intestinal POβ‚„ absorption
FGF-23 (from bone)↓↓Major phosphaturic hormone; also inhibits 1Ξ±-hydroxylase

PART 5: INSULIN - STRUCTURE AND RECEPTOR

What is insulin?

Insulin is a polypeptide hormone made by beta (Ξ²) cells in the islets of Langerhans of the pancreas. It is the key that "unlocks" cells to let glucose in. Without insulin, glucose can't enter most cells β†’ stays in blood β†’ diabetes mellitus.
Pancreatic islet cell types:
  • Ξ± cells (25%) - Glucagon
  • Ξ² cells (60%) - Insulin
  • Ξ΄ cells (10%) - Somatostatin
  • PP cells (5%) - Pancreatic polypeptide

Insulin Structure

  • Molecular weight: 5,808 Da
  • Two chains: A chain (21 amino acids) + B chain (30 amino acids)
  • Connected by: 2 disulfide bonds between chains + 1 within the A chain
  • If you split the two chains apart, insulin completely loses its activity

Insulin Biosynthesis Pathway

Gene on chromosome 11
      ↓ Transcription + Translation on ribosomes (RER)
PREPROINSULIN (110 amino acids, MW ~11,500)
      ↓ Signal peptide cleaved in ER lumen
PROINSULIN (86 amino acids, MW ~9,000) = A chain + B chain + C peptide
      ↓ Packaged in Golgi vesicles
      ↓ Cleavage by prohormone convertases (PC1 and PC2) + CPE
INSULIN (A+B chains, MW 5,808) + C PEPTIDE (31 amino acids)
      ↓ Both secreted together in EQUIMOLAR amounts from secretory granules

How Glucose Triggers Insulin Secretion

Glucose enters Ξ²-cell via GLUT2 (passive)
      ↓
Glucokinase (Hexokinase IV) phosphorylates glucose β†’ G-6-P
      ↓
Glycolysis + TCA cycle β†’ ATP production
      ↓
↑ ATP/ADP ratio
      ↓
ATP-sensitive K⁺ channel (KATP channel) CLOSES
      ↓
Ξ²-cell membrane DEPOLARIZES
      ↓
Voltage-gated Ca²⁺ channels OPEN
      ↓
Ca²⁺ floods into β-cell
      ↓
Insulin granules FUSE with membrane β†’ EXOCYTOSIS of insulin + C-peptide
Two phases of insulin secretion:
  • Phase 1 (3-5 min): Rapid dump of pre-stored insulin granules
  • Phase 2 (15 min to 2 hrs): Slower, sustained secretion from newly synthesized insulin

Insulin Receptor Signal Transduction

The insulin receptor is a Receptor Tyrosine Kinase (RTK) - a heterotetramer: 2Ξ± subunits (extracellular, bind insulin) + 2Ξ² subunits (transmembrane + intracellular kinase domain).
Insulin binds Ξ± subunit
      ↓
Ξ² subunit AUTOPHOSPHORYLATES (on tyrosine residues)
      ↓
Phosphorylates IRS-1/IRS-2 (Insulin Receptor Substrate proteins)
      ↓
       β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
       ↓                                 ↓
PI3K β†’ PIP3 β†’ PDK1 β†’ Akt            Grb2/SOS β†’ Ras β†’ ERK
(Metabolic effects:                   (Mitogenic effects:
 GLUT4 translocation,                  cell growth,
 glycogen synthesis,                   gene expression,
 lipogenesis,                          differentiation)
 protein synthesis)
The most important metabolic effect: Akt phosphorylates AS160 β†’ releases GLUT4 vesicles β†’ GLUT4 moves to cell surface β†’ glucose enters the cell.

PART 6: ROLE OF C-PEPTIDE

C-peptide = "Connecting peptide" - the middle chunk of proinsulin that gets cut out during insulin processing.

Why Does C-Peptide Matter?

1. Diagnostic use:
  • Injected insulin has no C-peptide
  • High insulin + Low C-peptide β†’ patient is injecting insulin (factitious hypoglycemia / insulin misuse)
  • High insulin + High C-peptide β†’ body is making too much insulin (insulinoma)
2. Beta cell function marker:
  • C-peptide measurement tells you how much insulin the pancreas is actually making
  • C-peptide has longer half-life (~35 min) vs. insulin (~5 min) β†’ easier to measure
  • Used to distinguish Type 1 DM (C-peptide absent/very low) from Type 2 DM (C-peptide normal/high)
3. Biological activity:
  • Binds a G-protein-coupled receptor
  • Activates Na/K-ATPase and eNOS (endothelial nitric oxide synthase)
  • May protect against diabetic nephropathy and neuropathy (role still being studied)

PART 7: GLUCAGON

What is glucagon?

Glucagon is made by alpha (Ξ±) cells of the pancreatic islets.
  • Insulin = fed state hormone (glucose ↑ β†’ insulin ↑ β†’ store energy)
  • Glucagon = fasting state hormone (glucose ↓ β†’ glucagon ↑ β†’ release energy)

Structure

  • 29 amino acid polypeptide
  • Made from proglucagon (158 amino acids)
  • Same proglucagon gene, but processed differently in intestinal L-cells β†’ makes GLP-1 instead

Stimulation and Inhibition

Stimulates GlucagonInhibits Glucagon
Low blood glucose (hypoglycemia)High blood glucose
Amino acids (alanine, arginine)Insulin
Fasting, exercise, stressSomatostatin
EpinephrineFree fatty acids
CortisolGLP-1

Glucagon Receptor and Mechanism

Glucagon receptor is a Class B GPCR.
Glucagon binds glucagon receptor on hepatocyte
      ↓
GΞ±s protein activates Adenylyl Cyclase
      ↓
ATP β†’ cAMP ↑↑
      ↓
Protein Kinase A (PKA) activated
      ↓
     β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
     ↓                                          ↓
GLYCOGENOLYSIS                           GLUCONEOGENESIS
(glycogen phosphorylase activated;       (PEPCK, fructose-1,6-
 PFK-2 inhibited)                        bisphosphatase activated)
     ↓                                          ↓
Glucose released from glycogen         New glucose from
into blood                             amino acids, lactate, glycerol
Additional glucagon effects:
  • Lipolysis: Activates hormone-sensitive lipase β†’ releases fatty acids from adipose
  • Ketogenesis: Promotes fatty acid oxidation β†’ ketone bodies in liver
  • Protein catabolism: Promotes amino acid release from muscle for gluconeogenesis

Glucagon Metabolism

  • Half-life: 3-6 minutes
  • Degraded primarily by: liver (first pass, ~60% removed) and kidneys
  • Mechanism: Proteolytic degradation by liver proteases + renal clearance

PART 8: SOMATOSTATIN

What is somatostatin?

Somatostatin is a universal inhibitory hormone - it shuts down multiple secretory processes simultaneously.
Made by:
  • Ξ΄ (delta) cells of the pancreatic islets
  • D cells of the stomach and intestine
  • Hypothalamus (inhibits growth hormone from pituitary)

Structure

  • Two forms: SS-14 (14 amino acids) and SS-28 (28 amino acids)
  • Both are cyclic peptides (linked by a disulfide bridge)
  • SS-14 predominates in pancreas; SS-28 predominates in intestine

What Triggers Somatostatin Release?

  • High glucose, amino acids, fatty acids after a meal
  • Other GI hormones (CCK, secretin)
  • High glucagon or insulin (local paracrine effect)

Somatostatin's Effects

TargetEffect
Pancreatic Ξ² cellsInhibits insulin secretion
Pancreatic Ξ± cellsInhibits glucagon secretion
PituitaryInhibits GH and TSH release
StomachInhibits gastrin, HCl, pepsin secretion
IntestineInhibits secretin, CCK, VIP, motilin
LiverInhibits bile flow
GI motilitySlows gastric emptying, reduces splanchnic blood flow
Memory trick: Somatostatin = the "bucket of cold water" thrown on every secretory process after a meal.

Mechanism of Action

  • Somatostatin receptors (SSTR1-5) are GPCRs coupled to Gi (inhibitory)
  • Gi β†’ inhibits adenylyl cyclase β†’ cAMP ↓ β†’ PKA activity ↓
  • Also: Opens K⁺ channels β†’ hyperpolarization β†’ inhibits Ca²⁺ entry β†’ inhibits exocytosis

Somatostatin Metabolism

  • Half-life: extremely short, 1-3 minutes in circulation
  • Degraded by peptidases in blood and tissues
  • This is why octreotide (tΒ½ 1.5 hours) and lanreotide (monthly depot) were developed
  • Clinical uses: acromegaly, carcinoid tumors, VIPomas, glucagonomas, bleeding esophageal varices

PART 9: GLUT TRANSPORTERS

What are GLUT transporters?

Glucose is a large, polar molecule - it cannot freely cross the lipid bilayer. It needs special protein channels called GLUT transporters (facilitative transporters - move glucose DOWN its concentration gradient, no energy needed).

The Key GLUT Transporters

GLUTLocationKm for GlucoseCharacteristicsRegulation
GLUT1RBCs, brain (BBB), placenta, fetal tissues1 mM (high affinity)Constitutive; baseline glucose transportNot insulin-regulated
GLUT2Liver, pancreatic Ξ²-cells, kidney, small intestine15-20 mM (low affinity)"Glucose sensor" - transports only when glucose abundantNot insulin-regulated
GLUT3Neurons (brain)1 mM (high affinity)Ensures neurons ALWAYS get glucoseConstitutive
GLUT4Skeletal muscle, cardiac muscle, adipose tissue5 mMThe insulin-regulated transporter; stored in intracellular vesiclesInsulin-dependent!
GLUT5Small intestine, spermHigh KmFructose transporter (not glucose)Constitutive

The Magic of GLUT4

At rest (no insulin): GLUT4 vesicles sit in the cytoplasm - very few on cell surface - little glucose enters muscle/fat.
After a meal (insulin released):
Insulin β†’ IR β†’ IRS-1 β†’ PI3K β†’ PIP3 β†’ Akt β†’ phosphorylates AS160
      ↓
TBC1D4 (AS160) inactivated
      ↓
Rab-GTPase proteins activated
      ↓
GLUT4 vesicles traffic to plasma membrane
      ↓
GLUT4 fuses with membrane (exocytosis) - increases 10-20 fold
      ↓
Glucose floods into muscle/fat cell
Clinical relevance: In Type 2 Diabetes, Akt/AS160 signaling is impaired (insulin resistance) β†’ GLUT4 doesn't move β†’ cells starve despite high insulin β†’ hyperglycemia.
Exercise effect: Exercise ALSO moves GLUT4 to the surface independently of insulin (via AMPK pathway) - this is why exercise lowers blood glucose even without insulin.

PART 10: LABORATORY DIAGNOSIS OF DIABETES MELLITUS

ADA Diagnostic Criteria (any ONE on TWO separate days, except symptomatic random glucose):

TestDiabetesPrediabetesNormal
Fasting Plasma Glucose (FPG)β‰₯ 126 mg/dL (7.0 mmol/L)100-125 mg/dL (IFG)< 100 mg/dL
2-hr Plasma Glucose (OGTT)β‰₯ 200 mg/dL (11.1 mmol/L)140-199 mg/dL (IGT)< 140 mg/dL
HbA1cβ‰₯ 6.5% (48 mmol/mol)5.7-6.4%< 5.7%
Random Plasma Glucoseβ‰₯ 200 mg/dL WITH symptoms--
The random glucose β‰₯200 + symptoms only requires ONE measurement.

PART 11: ORAL GLUCOSE TOLERANCE TEST (OGTT)

Procedure

  1. Patient fasts 8-14 hours overnight; normal carbohydrate diet (β‰₯150g/day) for 3 days prior; no heavy exercise 3 days prior
  2. Fasting blood sample taken
  3. Patient drinks 75g anhydrous glucose dissolved in 250-300 mL water (within 5 minutes)
  4. Blood samples taken at 1 hour and 2 hours
  5. Patient sits quietly, no smoking during test

Interpretation

2-hour valueInterpretation
< 140 mg/dLNormal glucose tolerance
140-199 mg/dLIGT (Impaired Glucose Tolerance) = Prediabetes
β‰₯ 200 mg/dLDiabetes Mellitus

For Gestational Diabetes (GDM)

  • 2-step approach (USA): 50g glucose screen at 24-28 weeks β†’ if β‰₯130-140 mg/dL at 1 hr β†’ 100g 3-hour OGTT
  • 1-step approach (international): 75g OGTT directly; GDM if fasting β‰₯92, 1-hr β‰₯180, 2-hr β‰₯153 mg/dL

PART 12: HbA1c (GLYCATED HEMOGLOBIN)

What is HbA1c?

When glucose is high in your blood, it spontaneously attaches to proteins in a non-enzymatic process called glycation. HbA1c is formed when glucose attaches to the N-terminal valine of the Ξ²-chain of hemoglobin.
High blood glucose + Hemoglobin A
      ↓ (non-enzymatic, irreversible, SLOW process)
Schiff base (unstable)
      ↓ Amadori rearrangement
HbA1c (stable ketoamine)

Why does it reflect 3-month glucose control?

  • RBCs live for approximately 120 days (3 months)
  • Every day the RBC lives, more glucose attaches to hemoglobin
  • The amount of HbA1c reflects the average glucose the RBC has been exposed to over its entire lifetime
  • HbA1c is a "memory" of blood glucose for the past 2-3 months
  • It reflects the last 30 days more heavily (because younger RBCs are more abundant)

Reference Values

HbA1cInterpretation
< 5.7%Normal
5.7 - 6.4%Prediabetes
β‰₯ 6.5%Diabetes mellitus (diagnostic)
Target < 7%Diabetic treatment goal (ADA)
> 8%Poor control, risk of complications

HbA1c to Average Blood Glucose Correlation

HbA1cEstimated Average Glucose
6%126 mg/dL
7%154 mg/dL
8%183 mg/dL
9%212 mg/dL
10%240 mg/dL

Conditions That Falsely Alter HbA1c

ConditionEffect on HbA1cReason
Hemolytic anemia↓ False lowRBCs destroyed faster β†’ less time for glycation
Iron deficiency anemia↑ False highRBCs live longer β†’ more time for glycation
Hemoglobin variants (HbS, HbC)UnreliableInterfere with assay
Pregnancy (2nd/3rd trimester)↓ False lowIncreased RBC turnover
Blood transfusion↓ False lowDilutes patient's own RBCs
High-dose vitamin C/E↓ False lowInhibit glycation
In conditions with abnormal RBC turnover β†’ use fructosamine (glycated albumin, reflects 2-3 week average) instead.

PART 13: METABOLISM OF INSULIN, GLUCAGON & SOMATOSTATIN

Insulin Metabolism

  • Normal fasting insulin: 5-15 ΞΌU/mL
  • After a meal, peaks at 50-100 ΞΌU/mL
  • Daily secretion: ~40-50 units/day
  • Half-life: ~5-8 minutes
Degradation sites:
  1. Liver - most important (~50% of portal insulin removed in FIRST PASS)
  2. Kidneys - second (~30-40% of peripheral insulin)
  3. Muscle, adipose - minor
Mechanism: Insulin-degrading enzyme (IDE = insulysin) - a zinc metalloprotease - degrades insulin in the cytosol after receptor-mediated endocytosis. Insulin-receptor complex is also internalized β†’ insulin degraded in lysosomes β†’ receptor recycled to surface.
Clinical relevance:
  • Kidney disease β†’ insulin half-life prolonged β†’ LESS insulin needed (risk of hypoglycemia)
  • Liver disease β†’ reduced first-pass extraction β†’ HIGHER systemic insulin levels

Glucagon Metabolism

  • Normal fasting glucagon: 75-150 pg/mL
  • Half-life: 3-6 minutes
  • Liver is the primary degradation site (60% removed in first pass)
  • Kidneys are secondary
  • Mechanism: Proteolytic degradation by liver enzymes + renal clearance

Somatostatin Metabolism

  • Half-life: 1-3 minutes (shortest of all three)
  • Mainly acts locally (paracrine) rather than as a true circulating hormone
  • Degradation: Plasma peptidases + liver + kidney clearance
  • Clinical consequence: Natural hormone is useless therapeutically β†’ synthetic analogs needed:
    • Octreotide (tΒ½ ~1.5 hours, SubQ injection 3x/day)
    • Lanreotide (depot injection, monthly)
    • Pasireotide (broader SSTR subtype binding, used in Cushing's disease)

QUICK REFERENCE MASTER TABLE

HormoneMade byChemical NatureReceptor TypeHalf-lifeMain Action
CortisolAdrenal zona fasciculataSteroid (C21)Nuclear60-90 minGluconeogenesis, anti-inflammatory
AldosteroneAdrenal zona glomerulosaSteroid (C21)Nuclear15-20 minNa⁺ retention, K⁺ excretion
TestosteroneTestes (Leydig cells)Steroid (C19)Nuclear2-4 hoursVirilization, anabolism
EstradiolOvaries (granulosa)Steroid (C18)Nuclear1-2 hoursFemale reproductive
T4 (Thyroxine)Thyroid follicular cellsIodinated amino acidNuclear (after β†’ T3)6-7 daysMetabolic rate (prohormone)
T3Peripheral conversionIodinated amino acidNuclear18 hoursMetabolic rate (active)
PTHParathyroid chief cellsPolypeptide (84 AA)GPCR (Gs+Gq)2-4 minRaise blood calcium
InsulinPancreatic Ξ² cellsPolypeptide (51 AA)Receptor tyrosine kinase5-8 minLower blood glucose, anabolic
GlucagonPancreatic Ξ± cellsPolypeptide (29 AA)GPCR (Gs β†’ cAMP)3-6 minRaise blood glucose, catabolic
SomatostatinPancreatic Ξ΄ cellsCyclic peptide (14 or 28 AA)GPCR (Gi β†’ ↓cAMP)1-3 minInhibit insulin, glucagon, GH

10 Key Concepts to Always Remember

  1. All steroid hormones come from cholesterol; the rate-limiting step is StAR protein moving cholesterol into mitochondria.
  2. Thyroid hormone synthesis needs iodine + TPO enzyme; T4 is a prohormone, T3 is the active hormone.
  3. TSH is the most sensitive thyroid test; low TSH = overactive gland, high TSH = underactive gland.
  4. PTH raises calcium AND lowers phosphate; Vitamin D raises both; FGF-23 lowers phosphate.
  5. Insulin is made as preproinsulin β†’ proinsulin β†’ insulin + C-peptide (released in equimolar amounts).
  6. GLUT2 is the glucose sensor in Ξ² cells (low affinity, high capacity); GLUT4 is insulin-regulated in muscle/fat.
  7. C-peptide helps distinguish endogenous insulin production from exogenous injection; also a marker of beta cell reserve.
  8. HbA1c reflects average blood glucose over 120 days (RBC lifespan); β‰₯6.5% = diabetes; target <7% in treatment.
  9. Glucagon β†’ GPCR β†’ cAMP β†’ PKA β†’ glycogenolysis + gluconeogenesis in liver.
  10. Somatostatin = master inhibitor of both insulin and glucagon via Gi β†’ ↓cAMP; half-life only 1-3 minutes.

Sources: Guyton & Hall Medical Physiology 14e | Harper's Illustrated Biochemistry 32e | Basic Medical Biochemistry 6e | Ganong's Review of Medical Physiology 26e | Tietz Textbook of Laboratory Medicine 7e | Harrison's Principles of Internal Medicine 22e | Costanzo Physiology 7e | Robbins & Kumar Basic Pathology | Quick Compendium of Clinical Pathology 5e
This is a shared conversation. Sign in to Orris to start your own chat.